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Kisspeptins, peptide products of KISS1, are endogenous ligands for 
KISS1R, a G protein-coupled receptor. In numerous cancers, KISS1 acts as a 
metastasis suppressor. However, studies have revealed that patients with 
elevated KISS1 and KISS1R breast tumor expression have increased tumor 
grade, increased lymph node metastases and poor survival. We hypothesize that 
depletion of KISS1R inhibits breast cancer cell metastasis. In order to assess the 
role of KISS1R in breast cancer metastasis, we used a pre-clinical orthotopic 
xenograft mouse model using MDA-MB-231 breast cancer cells for breast tumor 
establishment. We discovered that depletion of KISS1R decreased primary tumor 
growth and reduced lung metastatic burden, suggesting that KISS1R plays a role 
in promoting breast cancer metastasis. Furthermore, we observed that 
kisspeptin-10 stimulation increased breast cancer cell invadopodia formation via 
a β-arrestin2 dependent mechanism. Overall, our results suggest that KISS1R 
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1.1.1 Breast Cancer Staging and Classification  
According to the Breast Cancer Society of Canada, breast cancer is the 
most diagnosed cancer in Canadian women over the age of 20 and the second 
leading cause of Canadian women cancer related deaths†. In 2013, 23 800 
Canadian women were diagnosed with breast cancer representing 26% of all 
diagnosed cancers in Canadian women†. Additionally, approximately 5000 
women in Canada died from breast cancer, accounting for 14% of all cancer 
related deaths†. Due to the high rates of incidence and death to Canadian 
women, it is clear that a better understanding of breast cancer is required in 
order to develop better therapeutics and clinical strategies to combat the disease.   
Breast cancer staging assesses the extent cancer has developed within 
the body and whether the cancer has spread to other tissues (Figure 1.1) (1). 
The American Joint Committee on Cancer (AJCC) has developed a system of 
breast cancer classification based on tumor origin, cellular characteristics and 
metastatic extent. Stages I-III are classified based on the range of initial primary 
tumor size and the extent of breast cancer cell spread to lymph nodes that 
surround the breast (1). Most often, breast cancer arises from breast epithelium 
in either ductal or lobular tissue of the mammary glands and is termed ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), respectively (2). In 
situ refers to non-invasive breast cancer in which the tumor is confined to the 
milk duct or lobules of the breast. At this point the tumor cells are confined to the 
tissue and are not a threat of undergoing metastasis and thus classified as 
benign hyperplasia. Cells in DCIS and LCIS demonstrate an increased number of 
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anaplastic and mitotic cells, pleomorphism, and central luminal necrosis due to 
lack of blood supply (3). As cancer progresses and begins to invade into the 
surrounding tissue, they are then classified as invasive and pose a great risk to 
metastasis. The most common invasive breast cancers are ductal carcinoma 
(IDC) and invasive lobular carcinoma. These cancers often demonstrate lymph 
node metastases. The final stage, Stage IV, represents breast cancer that has 
metastasized to distant organs, such as bone, lung and brain, at which point the 





Figure 1.1. The steps of breast cancer progression. Non-malignant epithelial 
cells proliferate uninhibited leading to ductal hyperplasia. Epithelial cells lose 
their normal phenotype as well as morphology and begin to assume an 
expression profile of mesenchymal cells indicative of carcinoma advancement. 
Ultimately, cancer cells will acquire the ability to invade and migrate into the 







1.2.1 Metastatic Cascade 
Metastasis is the process by which cancer cells leave the primary tumor 
and disseminate to secondary sites within the body either through the blood 
circulatory system, the lymphatic system or within body cavities (Figure 1.2)(5). 
When breast carcinomas are confined to breast tissue, 5-year survival rates 
exceed 90% (6). However, long-term survival is significantly decreased when 
cancer cells metastasize and survival time is adversely affected depending on 
the extent and sites of colonization (7).  The initial step of the metastatic cascade 
involves a subpopulation of non-malignant cells accumulating mutations causing 
a malignant phenotype (8). In the context of breast cancer carcinoma, a tumor 
develops when epithelial cells undergo malignant transformation resulting in 
increased cellular proliferation and cell survival (9). Cancer cell survival is 
achieved through the development of anchorage independent growth and 
evasion of apoptotic signaling (5).  
Angiogenesis, the process of new blood vessel formation from previous 
vasculature, is an important event that regulates tumor growth and survival (10).  
Under normal physiological conditions, angiogenesis plays an important role in 
wound healing, placentation during pregnancy and in utero cell proliferation 
during the female reproductive cycle (11). Angiogenesis is precisely controlled 
through a balance of pro- and anti-angiogenic factors. In disease, this balance of 
pro- and anti-angiogenic growth factors is lost. In cancer, a plethora of pro-
angiogenic factors are released inducing tumor-associated microvasculature 
(12). This tumor-associated microvasculature is essential for tumor growth and 
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survival for the new blood vessels supply nutrients and oxygen that regulates 
tumor growth and size (13). Thus, the amount of tumor-associated 
microvasculature, or tumor microvessel density, is used as a prognostic marker 
for cancer stage and progression (14, 15). In these circumstances, blood vessel 
formation can arise from pre-existing vasculature from the host or originate from 
the cancers cells themselves in a process known as vascular mimicry (16). The 
molecular events underlying angiogenesis are stimulated under hypoxia 
conditions. As tumors increase in size, the availability of oxygen for each 
individual cell becomes exhausted and results in a hypoxic state. Under hypoxic 
conditions, the hypoxia inducible factor-1 (HIF-1) transcriptional complex 
becomes activated and induces promotion of pro-angiogenic factors, apoptotic 
resistance, anaerobic metabolism, and resistance to apoptosis (17). The vascular 
epithelial growth factor (VEGF) is a pro-angiogenic factor that has been 
demonstrated to play an important role in cancer induced angiogenesis. VEGF is 
created by tumor cells themselves or is released from the degradation of 
extracellular matrix (ECM) that surrounds the tumor (10). VEGF will then diffuse 
into the surrounding tissue and bind to VEGF receptors on the endothelial cells of 
pre-existing blood vessels, stimulating endothelial cell proliferation (10). The new 
endothelial cells form new networks of immature vessels within and surrounding 
the tumor. Often these immature vessels are fenestrated providing an opportunity 
for cancer cell metastasis (8). 
 Initial cell spreading or dissemination occurs in a process known as 
epithelial-to-mesenchymal transition (EMT), where epithelial cells lose cell-to-cell 
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adhesion, lose cellular polarity, and gain a mesenhymal phenotype of invasion 
and migration (18). Under normal physiological conditions, epithelial cells are 
organized in continuous sheets of polarized cells conveyed by cell-cell 
connections accomplished by gap and tight junctions, desmosomes, and 
adherens junctions (19). Furthermore, epithelial cells demonstrate an apical-
basolateral polarity organization which prevents individual cells from migrating. 
During EMT, epithelial cells will lose cellular polarity and cell-cell contact via 
deceased expression of important adhesion molecules such as E-cadherin (20). 
Concurrently, an increase in mesenchymal markers is observed. These markers 
include matrix metalloproteases (MMP), N-cadherin, vimentin, β-catenin, and 
Snail/Slug conferring a highly mobile disorganized cellular morphology (18). Cells 
which undergo EMT migrate away from the primary tumor through cellular cycling 
of adhesion/ de-adhesion molecules regulated by integrins and the formation of 
F-actin stress fibers through which myosin cycling initiates movement (5).   
 In combination with cell migration, cancer dissemination requires cells to 
invade through the underlying basement membrane, that surrounds the tumor, 
and into the surrounding ECM (8). For invasion to occur, the tumors cells must 
induce ECM remodeling to allow movement of the cancer cell. Cancer cells 
secrete several proteases that confer ECM remodeling (21). The most common 
proteolytic enzymes involved in metastasis are MMPs, cathepsins and urokinase-
type plasminogen activators (uPA) (21-23). Activation of these proteases during 
cancer metastasis results in uncontrolled degradation of the basement 
membrane and ECM. The degradation of ECM results in the release of growth 
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factors such as the epidermal growth factor (EGF) and VEGF, further contributing 
to local angiogenesis and metastatic progression (24). 
After the tumor cells have invaded and migrated through the basement 
membrane and surrounding stromal compartment, they will reach the newly 
formed tumor-associated microvasculature formed through the angiogenesis 
process. Due to the highly fenestrated nature of these vessels, tumor cells can 
enter the blood vessels through the event known as intravasation (24). Tumors 
cells will bind to endothelial cells inducing endothelial cell retracting and tumor 
cell entrance into cardiovascular circulation (24). Additionally, tumor cells may 
enter circulation through the lymphatic system. Due to the lack of tight junctions 
between endothelial cells in the lymphatic system, as opposed to the 
cardiovascular system, tumor cells may pass more easily through lymphatic 
endothelial cells (8). Once in cardiovascular or lymphatic circulation, tumor cells 
must survive by evading immune system destruction. One mechanism of survival 
is achieved through tumor cell clumping with other cells to help to create a 
physical barrier from the immune system (25). This clumping can occur with 
other cancer cells or with cells of the circulation system, such as blood platelets 
(24). At distant sites within the body, the cancer cells arrest in capillary beds, 
bind to endothelial cells and enter surrounding tissue in the process of 
extravasation (26). Metastasized cells may undergo apoptosis, however the few 
that survive can lay dormant for an extended length of time or proliferate 
immediately establishing a secondary tumor site (27). Similar to primary tumor 
growth, the secondary tumor requires angiogenesis to supply the growing tumor 
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and may act as a barrier to secondary tumor proliferation if angiogenesis cannot 
be induced (27). Once secondary tumors are established successful medical 
intervention is limited and the lethal effects of cancer result. It is proposed that if 
a cancer cell cannot complete any step of the metastatic cascade, metastasis will 
be inhibited. However, due to the number of complementary molecular signaling 
pathways that are involved in each step of metastasis, identifying effective 





Figure 1.2. The metastatic cascade. In order for cancer cells to spread to 
distant tissues, they must undergo several events that make up the metastatic 
cascade. The initial step is the formation of the primary tumor through 
proliferation of cancer cells (i). As the tumor progresses, some cancer cells will 
leave the primary tumor through invasion and migration into the surrounding 
tissue (ii). Tumor cells stimulate the formation of new blood vessels enabling 
tumor growth (iii). Eventually, some cancer cells will enter blood vessels through 
intravasation (iv) and survive in circulation (v). At distant tissues some cancer 
cells will leave blood vessels through extravasation (vi) and colonize at 




The ability of cancer cells to metastasize is dependent on the formation of 
the cellular structure known as invadopodia. Invadopodia are actin rich 
membrane protrusions formed on cancer cell surfaces that contribute to invasion 
through focal delivery of proteases (29). Structurally, invadopodia are recognized 
as punctate actin structures on the ventral surface of cells with co-localization of 
cortactin and associated underlying degradation (30). In vivo evidence 
demonstrates that invadopodia formation is directly involved in primary tumor 
invasion of the underlying basement membrane and ECM (31, 32). Furthermore, 
when invadopodia formation is inhibited, cancer metastasis is inhibited through 
the reduction of cancer cell intravasation and extravasation (31, 32). 
Invadopodia formation occurs through several stages from initial formation 
to final maturity. Each stage of invadopodia is dependent on the coordinated 
activation and localization of several proteins (Figure 1.3). Invadopodia formation 
is stimulated by various growth factors, such as the epidermal growth factor, 
leading to the invadopodia precursor organization (29, 33, 34). The invadopodia 
precursors are involved with binding to actin and inducing actin polymerization 
forming the invadopodia structure (35). The first major invadopodia precursor 
involved is the actin binding protein known as cofilin, which functions to cleave 
actin filaments to create new barbed end actin formations (36). Theses actin 
barbed end formations provide sites for actin polymerization and invadopodia 
extension (36). Two primary mechanisms of cofilin regulation have been 
proposed. The first mechanism involves blocking the binding of cofilin to actin via 
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serine phosphorylation at residue 3 by LIM-kinase 1 (37). The second 
mechanism is blocking cofilin’s ability to bind to actin through the binding of 
phosphorylated cortactin to cofilin (38). The second major invadopodia precursor 
is cortactin. Cortactin’s function is to promote invadopodia formation through 
actin binding and complexing with Arp2/3-N-WASP-dynamin, to promote actin 
polymerization and invadopodia protrusion (32). Cortactin is a major Src 
substrate where several tyrosine residues act as on/off switches for cortactin 
activity. Src phosphorylation at residues Y421, Y466, and Y482 act as an 
inhibitory mechanism by inhibiting the interaction and activation of N-WASP (39, 
40). When the mechanism of cofilin and cortactin control goes unchecked, 
invadopodia formation is favored, promoting cancer cell invasion and metastasis 
(41). Finally, invadopodia maturation occurs when the invadopodia acquire its 
matrix degradation ability.  
The invasive ability of invadopodia is mediated by the membrane bound 
matrix degradation protein, MT1-MMP. An accumulation of MT1-MMP occurs in 
invadopodia which in turn degrades the extracellular matrix (ECM) and basement 
membrane components including fibronection, laminins 1 and 5 and collagen I, II, 
and III (42). In vitro studies have demonstrated that MT1-MMP is required for 
cancer cell migration and invasion through Matrigel, an ECM mimetic (43). 
Furthermore, MT1-MMP, as opposed to MMP-2 or MMP-9, is responsible for 
invasion of cancer cells through the basement membrane, establishing an 
essential role for MT1-MMP in the initiation of metastasis (44). Upon invadopodia 
stimulation and formation, newly synthesized or recycled MT1-MMP molecules 
13 
 
are delivered to the invadopodia tip. The scaffolding protein IQGAP1, which 
provides a link between microtubule and actin cytoskeleton networks, 
coordinates vesicle-tethering of the exocyst complex for MT1-MMP surface 
delivery (45, 46). Upon activation of small GTPase RhoA, IQGAP1 complexes 
with the exocyst vessel containing MT1-MMP providing focal degradation (45). 
Whether MT1-MMP activity can be stimulated by receptors is unknown and is a 





Figure 1.3. Invadopodia formation and activity. Growth factor stimulation 
induces invadopodia formation through invadopodia precursor organization. 
Cofilin initiates actin polymerization by severing actin filaments to generate free 
actin barbed ends (i). Cortactin binds to actin filaments at actin barbed end 
formations and favors actin polymerization by recruiting the N-WASP Arp2/3 
complex (ii). MT1-MMP is transported to the invadopodia tip by microtubule 
vesicle trafficking and IQGAP1 coordinates exocyst release of MT1-MMP onto 
the invadopodia surface (iii). MT1-MMP causes extracellular matrix degradation 




1.3.1 Metastasis Suppressor Genes 
Breast tumorgenesis, the transformation of non-malignant cells to cancer 
cells, begins in breast cells of varying types and due to either genetic or 
environmental factors inducing a malignant change (47). The cancer cells exhibit 
specific characteristics not seen in non-malignant cells such as loss of 
differentiation, loss of apoptotic signaling, promotion of angiogenesis, loss of cell-
cell contact, evasion of host immune system, and immortalization (47). It has 
been proposed that cancer arises from the accumulation of mutations in genes 
that affect key cellular pathways involved in growth and development leading 
malignant capacity (48).  These alterations can occur within malignant cells or 
within host cells that surround malignancy such as vascular or immune cells (47, 
49). Recently, a new classification of genes have been discovered which are 
involved in tumor progression as opposed to tumor initiation. These genes are 
known as metastasis activator and metastasis suppressor genes. Unlike 
oncogenes or tumor suppressor genes, metastasis activator or suppressor genes 
do not affect the primary tumor tumorgenicity, but instead are involved in the 
ability of cancer cells to metastasize to distant tissue areas (50). Several 
metastatic suppressor genes have been identified whose expression have shown 
to disrupt the metastatic cascade, rendering metastatic cells non-metastatic. A 
few examples are NME1, MKK4, KAI1, E-cadherin, and KISS1 (51). Due their 
ability to inhibit metastasis without blocking primary tumor growth, metastasis 
suppresser genes provide a promising option for the development of therapeutic 
strategies in the prevention of metastatic disease. 
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1.3.2 KISS1 and KISS1R Discovery 
KISS1, a metastasis suppressor gene, was originally identified by Lee and 
colleagues in 1996 (50). To investigate what governs the ability of cells to 
undergo metastasis, Lee and colleagues used subtractive hybridization to 
determine the gene expression differences between two melanoma cell lines, the 
non-metastatic neo6/C8161.1 and metastatic cells C8161. Lee and colleagues 
discovered that an unidentified cDNA sequence encoding for a 164 amino acid 
protein was amplified in the non-metastatic neo6/C8161.1 cell line in comparison 
to the metastatic C8161 cell line (50). This unknown cDNA was termed KISS1 
gene. Since then, studies have shown KISS1 mRNA expression in the placenta, 
testis, brain, pancreas, liver, ovaries, small intestine, heart, skeletal muscle, 
breasts, kidneys, and lungs (52, 53). KISS1 gene encodes a 145 amino acid 
peptide that is cleaved to 10, 13, 14, or 54 amino acid lengths (53, 54). These 
secreted proteins are called kisspeptins (KP) and the smallest active form KP-10, 
is comprised of the amino acid sequence H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-
Arg-Phe-NH2 (55). This sequence is conserved over an assortment of species, 
differing from the human sequence by a single amino acid in sheep, mouse, rat, 
and cow (56). Using saturation binding experiments to kisspeptin receptor 
(KISS1R), KP-10 exhibits a KD of 1.0 ± 0.1 nM (52, 53, 56). Additionally, KP-10 
presents higher potency than KP-54 (EC50 5.47 ± 0.03 nM), KP-14 (EC50 7.22 




The kisspeptin receptor (KISS1R; formerly known as AXOR12, GPR54 or 
hOT7T175) was originally identified as orphan receptor GPR54 by three 
independent groups (52, 53, 57). Placental tissue extract was used to purify 
peptides to stimulate biological activity of GPR54 and mass spectrometry 
revealed these to be KISS1 gene products, kisspeptin (53). KISS1R expression 
as determined using reverse transcription polymerase chain reaction was found 
in breast, ovary, placenta, pituitary, spinal cord, pancreas, thymus, stomach, 
kidney, small intestine, lung, testis, and brain regions (52, 53, 57).  
1.3.3 KISS1R Signaling 
  KISS1R is a G protein-coupled receptor (GPCR) that signals through the 
Gq/11-coupled pathway leading to activation of phospholipase C (PLC) (Figure 
1.4). PLC signaling in turns causes an increase in inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol formation, an increase in intracellular calcium, and 
activation of protein kinase C and extracellular signal-regulated kinase (ERK) 1/2 
(52, 53, 57). Additionally, KISS1R has been shown to signal through a G-protein 
independent pathway via β-arrestin2, leading to activation of extracellular signal-
regulated kinase 1/2 (ERK1/2) (58). KISS1R is able to constitutively associate 
with β-arrestin1 and β-arrestin2, through residues in the second intracellular loop 
and cytoplasmic tail of KISS1R (59). It has been shown that β-arrestin-1 can 
inhibit KISS1R signaling whereas β-arrestin-2 stimulates KISS1R signaling to 
ERK1/2 (60). With the diverse ability of KISS1R to induce cellular signaling, 
understanding the effects of KISS1R signaling is necessary to determine if 






Figure 1.4. KISS1R signaling pathways. KISS1R is a Gq/11 coupled receptor 
which activation leads to extracellular signal-regulated kinases (ERK1/2) 
activation and phospholipase C (PLC) stimulation, calcium mobilization and 
protein kinase C (PKC) activity. KISS1R activation can also signal through a G 




1.3.4 Physiological Roles of KISS1R 
KISS1R signaling plays a significant role in initiation of puberty as defined 
by sexual development, increased bodily growth, and adrenal maturation. 
Seminara and colleagues first discovered that a homozygous mutation, L148S, in 
KISS1R caused autosomal recessive idiopathic hypogonadotropic hypogonadism 
in humans (61). Neuroendocrine research has demonstrated that secretion of 
kisspeptin, resulting in KISS1R signaling, conveys control of the reproductive 
axis by regulating gonadotropin-releasing hormone (GnRH) release (61-66). 
Kisspeptin is secreted in a pulsatile fashion from the arcuate nucleus of the 
hypothalamus (67). The kisspeptins in turn act on KISS1R in the median 
eminence to cause the release of GnRH into the hypophyseal portal which is 
then delivered to and acts on anterior pituitary to cause the release of the 
gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
(67). Mice with mutations of the Kiss1r or Kiss1 gene fail to achieve puberty 
establishing an essential role for KISS1R signaling during puberty development 
(61). Furthermore, Kiss1r-null mice demonstrate a decrease in LH and FSH 
serum levels suggesting a crucial role for KISS1R in LH and FSH secretion (61-
66). Further studies using KISS1-null mice demonstrated that LH and FSH serum 
levels could be recovered through subcutaneous injections of kisspeptin-54 
which resulted in GnRH release and puberty initiation (66). Finally, studies using 
the KISS1R antagonist (P-234) in pre-pubertal rats demonstrated that central 
injection of the antagonist could inhibit kisspeptin mediated signaling and delay 
puberty (68). Thus, research in kisspeptin signaling has established that KISS1R 
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activity is the major regulator of pubertal onset and the major regular of the 
hypothalamic-pituitary-gonadal (HPG) axis in several species including humans. 
 Additionally, kisspeptin/ KISS1R signaling plays an important role in 
pregnancy and placentation. High levels of KISS1 and KISS1R gene expression 
is found in the human placenta (50, 52, 53, 56, 57). During pregnancy, kisspeptin 
and KISS1R expression decreases from first trimester to the third, which 
correlates with decreased placental tissue invasion (69, 70). Conversely, 
circulating kisspeptin concentrations are increased 1000 fold during the first 
trimester and increases to 10,000 fold by the third trimester (69). The varying 
expression levels during pregnancy suggest a regulatory role of trophoblastic 
invasion during placentation. In vitro studies have demonstrated that kisspeptin-
10, the kisspeptin splice variant found in the placenta, inhibits migration of 
trophoblastic cells and decreases MMP expression which is required from 
placental invasion into the uterine walls (71). Furthermore, studies have revealed 
an important role for kisspeptin/ KISS1R signaling in maternal artery formation, 
required for proper fetal development (71). 
1.3.5 KISS1R Signaling In Cancer 
The KISS1 gene was originally identified by Lee and colleagues in 1996 
as metastasis suppressor gene in melanoma (50). Since this original discovery, 
kisspeptin/KISS1R signaling has been further identified to suppress metastasis in 
bladder (72), esophageal (73), lung (74), thyroid (75, 76), gastric (77, 78), 
ovarian (79-82), and pancreatic (83) cancers. In these cancers, KISS1R 
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expression was found to decrease in cancer cells compared to non-malignant 
tissue which correlates with poor prognosis in patients. The first study which 
examined KISS1 signaling in melanoma found that KISS1 mRNA expression was 
found only in non-metastatic melanoma cell lines and absent in metastatic 
melanoma cells. Furthermore, when KISS1 was overexpressed, melanoma cell 
motility was decreased and metastasis was suppressed in an expression-
dependent manner (50). A second study investigated KISS1 expression in 
various stages of melanocytic tumors found an inverse correlation of KISS1 
expression and melanoma metastases (60). When examination of pancreatic 
cancer tissues were performed,  a lower expression KISS1 mRNA was observed 
in pancreatic cancer as compared to non-malignant tissue (83). Likewise, when 
exogenous KISS1 gene was added to pancreatic cancer cells, a reduced 
migration of pancreatic cancer cells occurred while having no effect on cellular 
proliferation (83). In gastric cancer, KISS1 mRNA expression was reduced in 
patients that had lymph node and liver metastases (77). Additionally, the lymph 
node and liver metastases demonstrated a reduction of kisspeptin protein 
expression as compared to the primary gastric tumor (78). Furthermore, KISS1R 
activity in gastric cancer decreases MMP-9 activity, inhibiting invasion, as well as 
increasing the tissue inhibitor of metalloprotease (TIMP)-1 (53, 77, 78). In ovarian 
carcinoma (79-82), esophageal squamous cell carcinoma (73), and bladder 
carcinoma (72), decrease in KISS1 and KISS1R expression was determined to 




1.3.6 KISS1R Signaling in Breast Cancer 
In contrast to its metastasis suppressor role in many cancers, studies 
indicate that kisspeptin/KISS1R signaling induces a detrimental outcome in 
breast cancer. In 2005, the first clinical study focusing on kisspeptin signaling in 
breast cancer was carried out. Using quantitative-PCR analysis, Martin and 
colleagues measured KISS1 and KISS1R mRNA expression in breast tumor 
tissue. An observation of KISS1 mRNA expression was seen to be increased in 
breast cancer tissue compared to non-malignant mammary tissue (7). 
Furthermore, the breast tumors that had lymph node metastasis demonstrated 
an increased KISS1 mRNA levels in comparison to lymph node negative breast 
tumors (7). However, KISS1R mRNA expression was not significantly different 
between breast tumors and non-malignant tissue or breast tumors that were 
lymph node positive or negative for metastases (7). Additionally, overexpression 
of KISS1 gene in the human breast cancer MDA-MB-231 cells increased cell 
invasiveness and decreased cellular adhesion (7). Finally, this study reported 
that KISS1 mRNA expression correlated with poorer prognosis suggesting that 
KISS1 gene expression could be used as a prognostic marker in breast cancer 
patients (7). 
In 2007, Marot and colleagues reported that estrogen status of breast 
tumors was correlated to KISS1 mRNA expression. This study observed that 
estrogen receptor (ER) α-positive primary breast tumors expressed sevenfold 
less KISS1 levels as compared to ERα negative breast tumors (84). Furthermore, 
post-menopausal women with ERα positive breast tumors that were treated with 
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the estrogen antagonist, tamoxifen, had higher expression of both KISS1 and 
KISS1R mRNA tumor levels (84). This elevation in KISS1 and KISS1R mRNA 
tumor levels correlated with reduced relapse-free survival (84). Moreover, KISS1 
mRNA expression was found to increase with breast tumor grade (84). To further 
evaluate the links between ERα status and KISS1 expression, this study used 
ectopic re-expression ERα in the ERα-negative MDA-MB-231 breast cancer cell 
line and a corresponding reduction in KISS1 mRNA expression was observed 
(84). Likewise, tamoxifen treatment in the ERα-positive MCF7 and T47D breast 
cancer cells resulted in an increased expression of KISS1 and KISS1R (84). This 
study concluded that KISS1 and KISS1R mRNA levels in breast tumors could be 
a marker of tumoral resistance to anti-estrogen treatment. Thus, clinical results 
report that kisspeptin/KISS1R signaling may play an important role in breast 
cancer progression; however the mechanism by which this occurs remains 
elusive.  
Presently, a single study has attempted to investigate a role for kisspeptin/ 
KISS1R signaling in the regulation of breast cancer metastasis. Cho and 
colleagues (2011) used a Kiss1r haploinsufficiency mouse model with the 
polyoma virus middle T antigen (PyMT) under the control of the mouse mammary 
tumor virus (MMTV) promoter (MMTV-PyMT) to investigate the effects of Kiss1r 
expression on breast cancer establishment and metastasis. The MMTV-PyMT 
mice model enables mammary epithelium transformation into multifocal 
mammary adenocarcinoma and lymphatic/lung metastasis (85). This study 
demonstrated that loss of Kiss1r expression in Kiss1r heterozygotic PyMT-
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Kiss1r+/− mice attenuated breast tumor initiation, growth, latency, multiplicity and 
lung metastasis as compared to the homozygotic PyMT-Kiss1r+/+ mice (86). To 
assess the mechanisms by which Kiss1r regulated metastasis, the authors 
extracted cells from the primary breast tumors of the PyMT-Kiss1r+/− and PyMT-
Kiss1r+/+ mice for in vitro analysis. Kisspeptin-10 stimulation of Kiss1r in the 
extracted cell cultures resulted in small GTPAse RhoA activation through a Gαq 
pathway (86). Interestingly, this study also observed that decreased Kiss1r 
expression correlated with a significant reduction in VEGF and MMP-9 mRNA 
suggesting a possible role for Kiss1r in both angiogenesis and breast cancer 
invasion (86). In conclusion, this study suggests kisspeptin/Kiss1r signaling via 
RhoA is required for breast cancer metastasis in mouse models. 
 Studies from our laboratory have provided some insight on the mechanism 
by which KISS1R stimulates breast cancer cell migration and invasion, two 
processes required for metastasis (87, 88). Our first study found that kisspeptin-
10 stimulation led to significant increase in MMP-9 secretion and activity in MDA-
MB-231 breast cancer cells suggesting a mechanism of breast cancer invasion 
(88). Most interestingly, we found that kisspeptin-10 induced EGFR 
transactivation in a β-arrestin2 dependent mechanism in ERα-negative breast 
cancer cells (88). Furthermore, FRET analysis revealed that KISS1R interacts 
directly with EGFR under basal conditions (88). We also found that KISS1R 
expression or kisspeptin-10 treatment stimulates EMT of ERα negative MCF10 
breast epithelial cells through the increase in N-cadherin and Snail/Slug 
expression resulting in increased cell invasiveness (87). Furthermore, 
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overexpression of exogenous KISS1R in ERα-negative SKBR3 breast cancer 
cells induced extravasation in vivo using the chick chorioallantoic membrane 
(CAM) assay (87). However, kisspeptin-10 treatment failed to induce 
invasiveness or EGFR transactivation in the ERα-positive MCF7 and T47D 
breast cancer cells suggesting that ERα negatively regulates KISS1R signaling in 
breast cancer (87). To confirm this, exogenous ERα was expressed in MDA-MB-
231 cells which resulted in decreased KISS1R expression and inhibited 
kisspepin-10 mediated effects on EGFR transactivation and cell invasion (87). 
Finally, the actin cytoskeletal binding protein, IQGAP1, was found to be a novel 
binding partner of KISS1R which regulated kisspeptin-10 induced EGFR 
transactivation (Figure 1.5) (87). However, whether human KISS1R signaling 









Figure 1.5. KISS1R signaling pathways in breast cancer. (i) Kisspeptin leads 
to KISS1R activation causing transactivation of epidermal growth factor (EGFR) 
via β-arrestin2 and IQGAP1 mediated mechanisms. (ii) KISS1R activation leads 
to epithelial-mesenchymal transition (EMT) causing a mesenchymal phenotype. 
(iii) Likewise, KISS1R activation leads to RhoA anchorage independent growth 
and cytoskeletal remodeling. (iv) Estrogen receptor, ERα, down regulates 






β-arrestin1 and β-arrestin2 are two isoforms of 78% identical amino acid 
sequence which have demonstrated a diverse set of roles in cells (90). Studies 
have demonstrated abundant expression of β-arrestins in numerous cell types 
and are involved in regulating receptor desensitization, internalization and 
signaling (91-95). The β-arrestin structure consists of two antiparallel β-sheet 
domains with a connecting hinge region and an α-helix amino-terminal tail which 
conveys cellular localization (96, 97). Additionally, the hydrophobic core interacts 
with phosphorylated residues, important in the interactions of β-arrestins and 
GPCRs. Under basal conditions, β-arrestins are phosphorylated on serine 412. 
Upon activation, dephosphorylation of serine 412 enables β-arrestin binding to 
other proteins such as Src (99). 
Originally, β-arrestins were discovered to be a regulator of GPCR 
desensitization and internalization. Desensitization and internalization are 
mechanisms by which receptor signaling leads to receptor internalization and 
directed to either the endosome for receptor recycling or to the lysosome for 
destruction (98, 99). During receptor internalization, β-arrestins function in 
coordinated effort with GPCR kinases (GRKs) to bind to the phosphorylated 
receptor being internalized (100). Desensitization is thought to be an adaptive 
response in order to prevent potential detrimental effects from continuous 
receptor stimulation (101). By dictating receptor recycling or destruction, 
internalization provides control of the duration and intensity of GPCR signaling by 
regulating the number of receptors available on the cellular surface for ligand 
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binding. Furthermore, the binding of β-arrestin to GPCRs inhibits receptor 
coupling to heterotrimeric G proteins, thus limiting G protein mediated signaling. 
However, receptor bound β-arrestin can mediate signaling, providing a G protein 
independent signaling cascade (102). β-arrestin acts as molecular scaffold by 
bringing signaling molecules in proximity to each other; these signaling proteins 
include, but are not limited to, Src, ERK1/2, and AKT (97, 103). 
1.4.2 β-arrestin and Breast Cancer 
β-arrestins are emerging as key regulators of tumorgenesis and metastasis. 
In breast cancer, β-arrestins have been shown to regulate breast cancer growth 
and proliferation (104). Depletion of β-arrestin1 expression in MCF-7 breast 
cancer cells inhibits ERK1/2 and c-JUN activity resulting in decreased cellular 
proliferation; thus, implicating a role for β-arrestins in the regulation of breast 
cancer cell growth (104). Additionally, β-arrestins regulate breast cancer 
migration and invasion (105-107). For instance, protease activated receptor 2 
(PAR2) signaling in MDA-MB-231 human breast cancer cells induced cell 
migration through a β-arrestin dependent ERK1/2 mechanism (107). Likewise, β-
arrestin expression is required for LPA1-stimulated migration of MDA-MB-231 
cells via small GTPase Ral and Rap (106). One proposed mechanism by which 
β-arrestin regulates cancer cell migration involves the interaction of β-arrestin 
with the actin filament-severing protein, cofilin. Activation of PAR2 in MDA-MB-
468 breast cancer cells leads to β-arrestin1 and β-arrestin2 binding to cofilin and 
co-localization to the leading edge of migrating cells (108). Furthermore, PAR2 
signaling through cofilin is necessary for actin cytoskeleton reorganization and 
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chemotaxis (109). Additionally, β-arrestins inhibit LIM kinase, the kinase that 
inhibites cofilin activation through serine phosphorylation (108). Moreover, global 
proteomics analysis has demonstrated that β-arrestins interact directly with cofilin 
and cortactin, two important proteins that regulate invadopodia formation (110). 
 Beyond primary growth, β-arrestins have also been implicated in the 
regulation of breast cancer metastasis. In 2011, Lundgren and colleagues 
investigated the expression of β-arrestin1 in clinical breast cancer samples. This 
study reported that elevated stromal β-arrestin1 correlated with poor patient 
survival (111). Further analysis revealed β-arrestin1 expression to positively 
correlate with tumor size, lymph node status, proliferation and distant metastases 
(111). Furthermore, this study showed that elevated stromal β-arrestin1 was 
linked to increased HIF-1α expression, suggesting a role for β-arrestin1 in 
angiogenesis (111). Thus, this study suggests that β-arrestin1 expression is a 
negative prognostic marker of patient outcome. A second study by Shenoy and 
colleagues (2012), examined β-arrestin1 protein levels in non-malignant and 
breast cancer tissues. Infiltrating ductal carcinoma tissue demonstrated elevated 
levels of β-arrestin1 in comparison to non-malignant breast tissue suggesting 
elevated β-arrestin1 correlates with breast cancer progression (112). 
Furthermore, this study used tail vein injection of MDA-MB-231 breast cancer 
cells in nude mice to examine the roles of β-arrestin1 and β-arrestin2 in breast 
cancer metastasis. Upon depletion of both β-arrestin1 and β-arrestin2, tumor 
growth was delayed and mouse survival increased, suggesting a role for β-
arrestins in breast cancer metastasis (112). Moreover, this study found that β-
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arrestin1 interacts with HIF-1α and controls HIF-1α nuclear trafficking suggesting 
a role for β-arrestin1 regulation of nuclear signaling under hypoxic conditions 
(112). Likewise, analysis of invasive human breast cancer samples revealed that 
increased β-arrestin1 expression correlates with increased levels of VEGF 
expression (112). Hence, this study suggests that β-arrestin1 regulates breast 
cancer survival and metastatic progression through regulation of pro-angiogenic 
factor expression and nuclear signalling. 
1.5.1 Rationale 
Clinical studies have established a potential role for KISS1R in breast 
cancer progression and metastasis (7, 84). Examination of KISS1 and KISS1R 
expression in breast cancer has revealed that KISS1 expression is elevated in 
human breast cancer tissues and correlates with increased tumor grade and 
lymph node metastasis (7). Furthermore, patients with high KISS1 and KISS1R 
mRNA expression had shorter relapse-free survival (84). Currently, the only in 
vivo study examining the role of KISS1R in breast cancer demonstrated that 
decreased mouse Kiss1r expression attenuated breast tumor initiation, growth, 
latency and metastasis in MMTV-PyMT/Kiss1r mouse models (86). However, a 
role for KISS1R signaling in regulation of human breast cancer metastasis 
remains unknown and will be investigated in this study.  In our laboratory, our 
earlier studies have shown that overexpression of exogenous KISS1R in ERα-
negative SKBR3 breast cancer cells increased cellular invasion and induced 
extravasation as revealed using the CAM assay (87). Additionally, we have found 
that kisspeptin stimulation of ER-negative breast cancer cells leads to increased 
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breast cancer cell invasion through kisspeptin-10 EGFR transactivation and 
increased MMP-9 activity via a β-arrestin2 dependent mechanism (88). β-
arrestins have been demonstrated to play a substantial role in breast cancer cell 
migration and invasion (88, 105, 106). Furthermore, β-arrestin has been 
established to regulate cofilin activity and bind to cortactin, two important proteins 
that regulate invadopodia formation. Nevertheless, whether β-arrestins regulate 
invadopodia formation and whether KISS1R signaling can promote invadopodia 
is unknown and will be investigated here.  
1.5.2 Hypothesis 
The depletion of KISS1R expression will inhibit human breast cancer cell 
metastasis. 
1.5.3 Objectives 
1) To investigate if KISS1R depletion inhibits human breast cancer 
metastasis using an orthotopic xenograft mouse model. 
2) To determine the underlying mechanisms of KISS1R signaling in breast 
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2.1 Materials and Methods 
Human Cell Culture. Two breast adenocarcinoma cancer cell lines were used 
for this study; the highly metastatic MDA-MB-231 and moderately invasive 
Hs578T cell lines (1). The MDA-MB-231 and Hs578T cell lines are estrogen 
receptor-α negative and endogenously express epidermal growth factor receptor 
and KISS1R (2, 3). Cell lines (all human, all female) were purchased from ATCC 
(Manassas, VA) and maintained at 37°C with 5% CO2. Breast cancer cells, MDA-
MB-231, MDA-MB-231 Scrambled control, MDA-MB-231 KISS1R shRNA #1,  
MDA-MB-231 KISS1R shRNA #2, MDA-MB-231 β-arrestin2 shRNA #1, MDA-
MB-231 β-arrestin2 shRNA #2, Hs578T, Hs578T Scrambled control, Hs578T 
KISS1R shRNA #1, and Hs578T KISS1R shRNA #2 are cultured in RPMI 1640 
(Invitrogen, Burlington, Ontario, Canada) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Sigma).   
 
Stable Transfections and Gene Knockdowns. Gene knockdown of KISS1R, β-
arrestin 1, β-arrestin 2 in MDA-MB-231 cells and Hs578T cells was achieved as 
previously described (2-4). HuSH vectors containing gene specific shRNA and 
scrambled controls (OriGene Technologies) were transfected into cells by 
electroporation (Gene Pulser Xcell, Bio-Rad), according to the instructions of the 
manufacturer (250 V, 950 μF). Heterogeneous populations of stable transfectants 
were selected using media containing puromycin (1.5 ng/mL) and expression of 
proteins was verified by Western blot analysis.  
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Spontaneous Metastasis Assay in NOD/SCID/IL2 receptor γ null Mice. To 
assess the role of KISS1R in regulating breast cancer metastasis, we used an 
established orthotopic spontaneous metastasis model using NOD/SCID/IL2 
receptor γ null immunocompromised mice as described previously (5). MDA-MB-
231 cells expressing scrambled control or KISS1R shRNA were resuspended in 
growth factor-reduced Matrigel (1:1) (1 x 106 cells/mice) and injected into the right 
thoracic mammary fat pad of 6 week old female NOD/SCID-IL2Rγ null mice (5 
mice/group). Tumor growth was evaluated by caliper measurement bi-weekly, in 
three dimensions. At 5 weeks post-injection, mice were sacrificed and primary 
tumor and the lungs, liver and mammary fat pads harvested.  Tissues were 
collected and fixed in 10% neutral-buffered formalin and embedded in paraffin as 
performed by the London Laboratory Services Group at the London Health 
Sciences Centre. Each tissue was sectioned 10 times at 4 μm thickness and the 
first and final section stained with hematoxylin and eosin for histological analysis 
and each adjacent section stained using anti-human Ki67 (1:100, Fisher) to 
measure human cell proliferation or with anti-mouse CD-31 (1:100, BD 
Bioscience) to measure blood vessel density. Lung metastatic tumor burden was 
quantified by measuring the number of metastatic tumors per mm2 and percent of 
lung area with metastases as assessed in each hematoxylin and eosin stained 
lung section using Aperio ImageScope software. Primary tumor blood vessel 
density was determined by counting the total number of blood vessels with CD-
31 positive staining and dividing by total tumor cross section area as determined 
using Aperio ImageScope software. All animal procedures were conducted in 
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accordance with the recommendations of the Canadian Council on Animal Care, 
under a protocol approved by the University of Western Ontario Council on 
Animal Care. 
 
Immunofluorescence Microscopy. Immunostaining was conducted as 
described previously (2, 3, 6). MDA-MB-231 and Hs578T cells expressing 
scrambled control or KISS1R shRNA were washed with Hank's Balanced Salt 
Solution, fixed and permeabilized with 4% paraformaldehyde and 0.2% Triton-X 
(room temperature, 20min). Phalloidin (1:100, Invitrogen) conjugated to Alexa 
Fluor (AF) 555 was incubated for 1 h. Nuclei were stained with 0.01% Hoechst 
33258 (Invitrogen). Cells were then washed with Hank's Balanced Salt Solution 
(HBSS) and slides mounted using Immuno Mount (Fisher) and #1 glass coverslip 
(VWR). Images were acquired using an LSM-510 META laser scanning 
microscope (Zeiss, Germany).  
 
Immunoblot Assays. MDA-MB-231 and Hs578T cells stably expressing 
scrambled control, KISS1R shRNA, β-arrestin2 shRNA, or β-arrestin1/2 shRNA 
were lysed using RIPA buffer (150 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 1% 
NP40, 0.1% SDS, 10 mM NaF, 0.5% deoxycholate, 10 mM sodium 
pyrophosphate, protease inhibitors). Protein (50 μg) was separated by SDS-
PAGE and protein expression was examined using either: goat anti-KISS1R (N-
20) sc-48220 (1:1000, Santa Cruz Biotechnology), rabbit anti-Snail/Slug (1:500, 
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Santa Cruz), mouse anti-β-catenin (1:1000, BD), rabbit smooth muscle actin 
(1:1000, Invitrogen), rabbit anti-laminin V (1:1000 Millipore), anti-β-arrestin1 (1: 
300, abcam),  anti-β-arrestin2 (1:500, abcam), anti-VEGF (1:200, Santa Cruz),  
anti-HIF-α (1:1000 Cell Signaling) and visualized by chemiluminescence. 
Densitometric analysis of protein bands was performed using VersaDoc Imaging 
System (Bio-Rad). Rabbit β-actin (polyclonal antibody, 1:2000; Sigma) 
expression was used to control for equal loading of samples.  
 
Scratch Assays for Cell Motility. MDA-MB-231 and Hs578T cells expressing 
shRNA targeting KISS1R or scrambled control were grown to 100% confluence 
in a 12-well plate, serum starved in RPMI 1640 media for 24 h, and scratched by 
a sterile pipette tip as described previously (2, 3). Cells in fetal bovine serum 
supplemented media were allowed to migrate into the scratch for 18 hours and 
imaged every 15 minutes using an automated Olympus IX-81 microscope. 
Distance travelled was measured and analyzed using ImagePro software. 
 
Cell Migration and Invasion Assays. Transwell chamber migration and 
Matrigel-invasion assays were conducted as described (2-4). Transwell filters (8 
µm pores) were placed into a 24-well plate containing either serum-free RPMI 
1640 media or media supplemented with 10% fetal bovine serum. Cells were 
serum-starved for 24 hours. MDA-MB-231 cells and Hs578T (4.0 x 104 cells for 
migration assay, 1.0 x 105 cells for invasion assay) expressing scrambled shRNA 
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control or KISS1R shRNA were plated in the upper chamber in either serum-free 
media or serum-free media supplemented with 100 nM kisspeptin-10 (Phoenix 
Pharmaceuticals) and incubated for 20 hours. All experiments were conducted 
with kisspeptin-10 concentration of 100 nM based on dose response studies 
conducted as described previously (3). For invasion assays, cells were 
suspended in 1 in 10 dilution of Matrigel (8.0 mg/mL, BD Biosciences) dissolved 
in serum-free RPMI 1640. Cells were then fixed with a 20% acetone: 80% 
methanol solution and nuclei stained with 0.1% Hoechst 33258 (Invitrogen). Two 
replicates were conducted for each condition and 12 fields (migration assay) or 
24 fields (invasion assay) in each replicate were chosen and counted using an 
Olympus IX-71 inverted microscope. Results are presented as a ratio of cells that 
migrated relative to cells that migrated or invaded in control conditions (cells 
seeded in serum-free media and migrating towards media with 10% (v/v) fetal 
bovine serum). 
 
Three-Dimensional Invasion Assays. These experiments were conducted as 
described previously (2, 3). Matrigel is effective for establishing both malignant 
and non-malignant breast cell growth, resembling what is occurring in the in vivo 
tumor micro-environment (2, 3, 6, 7). MDA-MB-231 and Hs578T expressing 
scrambled control or KISS1R shRNA (2.5 × 104 cells/mL)  were seeded in a 1:1 
dilution of phenol red-free Matrigel and culture media on Matrigel-coated glass-
bottomed culture dishes (35 mm, MatTek). Cultures were overlaid with culture 
media and maintained for five days. Cell colonies were scored blindly as being 
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either stellate or spheroidal. A colony is deemed to be stellate if one or more 
projections from the central sphere of a colony of cells are observed. Images 
were taken with an Olympus IX-81 microscope (Olympus), using InVivo Analyzer 
Suite (Media Cybernetics).  
 
Anchorage-Independent Growth Assay. This assay was conducted as 
described (8). One to one dilution of 1.2% agarose (in media) was layered over 
3.5 mm wells to form a base. MDA-MB-231 cells (5.0 x 103) expressing 
scrambled control or KISS1R shRNA were suspended in 1 to 1 dilution of 0.6 % 
agarose in 10% (v/v) fetal bovine serum supplemented with RPMI 1640 medium 
and allowed to grow for five weeks to form colonies. Colonies were stained with 
crystal violet, imaged with Olympus IX-71 inverted microscope and analyzed 
using ImagePro software (Media Cybernetics). 
 
Invadopodia Formation Assay. To assess the ability of cells to form 
invadopodia, a gelatin degradation assay was performed using QCM™ Gelatin 
Invadopodia Assay kit (Millipore), as described by the manufacturer. Briefly, an 8-
well chamber slide was coated with poly-L-lysine, followed by glutaraldehyde, 
and then fluorescent-gelatin. Following gelatin incubation, each well was 
incubated with RPMI 1640 growth media for 30 minutes to quench residual free 
aldehydes. Finally, MDA-MB-231 (75,000 cells/cm2) and Hs578T (60,000 
cells/cm2) cells were plated in RPMI 1640 growth media and incubated at 37°C 
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with 5% CO2 for 24 hours. After incubation, cells were treated with 100 nM 
kisspeptin-10 and/or 1 μM P-234 (KISS1R antagonist) for 30 minutes, or left 
unstimulated. Following treatment, cells were washed with HBSS, fixed and 
permeabilized with 4% paraformaldehyde and 0.2% Triton-X (room temperature, 
20min) and blocked with 3% bovine serum albumin. The primary antibody for 
cortactin (anti-cortactin antibody, ab33333, abcam) was incubated for 1 hour. 
After primary antibody incubation, the following secondary antibodies anti-mouse 
DyLight 350 (Thermo/Pierce) and TRITC-phalloidin (2 μg/mL) were incubated 
with the cells for 1 hour. Cells were washed with HBSS and slides mounted using 
Immuno Mount (Fisher) and #0 coverslip (VWR). Images were acquired using an 
LSM-510 META laser scanning microscope (Zeiss, Germany).  
 
Co-localization of Proteins in Invadopodia. To assess the distribution and 
localization of endogenous proteins within invadopodia, the gelatin degradation 
assays were performed as described above, using fluorescein free gelatin. 
Briefly, after 30 minutes of 100 nM kisspeptin-10 stimulation, cells were washed 
with HBSS, fixed and permeabilized with 4% paraformaldehyde and 0.2% Triton-
X (room temperature, 20min) and blocked with 3% BSA. The following primary 
antibodies were incubated for 1 hour; anti-KISS1R (N-20) sc-48220 (1:100, 
Santa Cruz Biotechnology), anti-cortactin (1:100, ab33333, Abcam), anti-MT1-
MMP (1:100, Abcam), anti-β-arrestin 2 (1:50, Santa Cruz Biotechnology), anti-
IQGAP1 (1:50, Santa Cruz Biotechnology), or anti-EGFR (1:50, Abcam). 
Subsequently the cells were incubated for 1 hour with the following secondary 
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antibodies: anti-rabbit Alexa Fluor (AF) 488 (1:250, Invitrogen), anti-goat AF 555 
(1:1000, Invitrogen), anti-mouse DyLight 350 (1:50, Thermo/Pierce) were 
incubated with the cells for 1 hour. Cells were washed with HBSS and slides 
mounted using Immuno Mount (Fisher) and #0 coverslip (VWR). Images were 
acquired using an LSM-510 META laser scanning microscope (Zeiss, Germany). 
 
Cortactin and Cofilin Phosphorylation. MDA-MB-231 cells expressing shRNA 
targeting either KISS1R or β-arrestin 2 or scrambled control were grown to 70% 
confluence, serum starved for 24 hours and then treated with 100 nM kisspeptin-
10 for either 5 or 15 minutes. Cells were lysed with RIPA lysis buffer (150 mM 
NaCl, 50 mM Tris pH8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF, 0.5% 
deoxycholate, 10 mM sodium pyrophosphate, and protease inhibitors) and 
proteins (50 μg) were separated by SDS-PAGE. The phosphorylation of cortactin 
(anti-cortactin (phospho Y421) antibody ab47768, Abcam) and cofilin (anti-cofilin 
(phospho S3 antibody, ab47281, Abcam) was visualized by chemiluminescence. 
Total cofilin (cofilin 1 (H-12) sc-32158, Santa Cruz) or total cortactin (anti-
cortactin antibody ab33333, abcam) expression was used to control for equal 
loading of samples. 
 
 MT1-MMP Phosphorylation. MDA-MB-231 cells were grown to 70% 
confluence, serum starved for 24 hours, and then treated with 100 nM kisspeptin-
10 for either 5 or 15 minutes. Cells were lysed with RIPA-modified lysis buffer 
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(150 mM NaCl, 50 mM Tris ph8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF, 
0.5% deoxycholate, 10 mM sodium pyrophosphate, and protease inhibitors). To 
immunoprecipitate MT1-MMP, cell lysates (800 μg) were incubated with anti-
MT1-MMP (1:200, Abcam) over-night at 4°C. Following antibody incubation, 
Dynabeads (Life Technologies) were added to lysates with the antibody for 30 
minutes at 4°C. Immunoprecipitated proteins were separated by SDS-PAGE and 
MT1-MMP phosphorylation was determined using a mouse monoclonal anti-
phosphotyrosine antibody (PY-20, Santa Cruz). MT1-MMP phosphorylation was 
normalized to total MT1-MMP expression as determined using a rabbit 
monoclonal anti-MT1-MMP antibody (1:100, Abcam). 
 
Extravasation In Chick Chorioallantoic Membrane (CAM) Assay. These 
experiments were performed as previously described (9-12). On day 12 of 
embryonic development, MDA-MB-231 cells expressing shRNA for either 
KISS1R, β-arrestin 2, or scrambled control were fluorescently labeled with 
CellTracker Green CMFDA (Life Technologies) and injected into a vein within an 
intact chorioallantoic membrane. Cells were pre-treated with 10 nM or 100 nM 
kisspeptin-10, 1 μM KISS1R antagonist P-234, 1 μM EGFR antagonist AG-1478, 
or vehicle (acetonitrile) treatment. Immediately after injection, aluminum foil with 
an inner square (1-cm2 region of interest (ROI)) was placed on the surface of the 
CAM for macroscopic imaging. The number of cells that arrested within the 
capillaries of the ROI were visualized using fluorescence microscopy and 
enumerated (t=0). At least 150 cells for each ROI at T=0 was analyzed and 
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enumerated. At 24 hours post injection, the ROI was examined again and cells 
that extravasated to the stroma were counted allowing percent cellular 
extravasation to be determined.  
 
MTT cell viability assays. These assays were conducted using cell proliferation 
kit I (MTT) (Roche) as previously described (2). MDA-MB-231 and Hs578T 
expressing scrambled control or depleted of KISS1R were seeded in triplicates in 
a 96 well plate and grown to 70% confluence. MTT labeling reagent (10 μl) was 
added to each well and cells were incubated for 4 h at 37°C and 5.0% CO2.  
Following incubation, 100 μl of solubilization reagent was added to each well and 
cells were incubated for 24 hours at 37 °C and 5.0% CO2.  Absorbance was then 
measured at 550 nm using a SpectraMaxM5MultiMode Microplate Reader 
(Molecular Devices) with a background subtraction at 700 nm. 
 
Cell Growth Assay. To determine the rate of cell growth in monolayer culture, 
2.0 x 105 MDA-MB-231 and Hs578T cells expressing either scrambled control 
shRNA or KISS1R shRNA were plated in 6-well culture plates. At 24 hour 
intervals (24, 48, and 72 hours) cell samples were dissociated using trypsin and 






One-way analysis of variance (ANOVA) with a Dunnett’s post-hoc test or two-
way ANOVA followed by Bonferroni post-hoc test was performed using 
GraphPad Prism 5 (GraphPad Software, Inc.). Differences were considered 
statistically significant at p<0.05. 
2.2 Results 
KISS1R depletion decreases tumor formation and lung metastasis in 
xenograft transplantation of human breast cancer cells in mice 
The orthotopic xenograft model has been used to effectively study 
spontaneous metastasis, allowing tumor cells to undergo all the steps of the 
metastatic cascade (5, 13, 14). Hence, to examine the role of KISS1R in breast 
cancer metastasis, we used an in vivo orthotopic xenograft spontaneous 
metastasis model in NOD/SCID/IL2 receptor γ null mice. For xenograft 
transplantation, the human adenocarcinoma breast cancer line MDA-MB-231 
was selected due to its highly metastatic characteristics and its endogenous 
expression of KISS1R (1). Using two different KISS1R shRNA constructs, 
KISS1R expression was depleted in MDA-MB-231 cells, as verified through 
western blot (Figure 2.1A) and did not affect cell viability (Figure 2.1B). The three 
MDA-MB-231 cell populations of scrambled control, KISS1R shRNA #1, and 
KISS1R shRNA #2 were injected into the right mammary fat pad of 6 week mice 
(5 mice per cell population). At 5 weeks post-injection, mice were sacrificed and 
the primary tumor, lung, liver and brain tissues were removed and examined. We 
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observed that upon depletion of KISS1R, primary tumor volume was reduced in 
the tumors with cells depleted of KISS1R compared to scrambled control (Figure 
2.1C). Furthermore, using hematoxylin and eosin (H&E) staining we observed a 
reduction of breast cancer metastasis to lung, where area of metastatic burden 
and the number of metastases was reduced in mice injected with cells depleted 
of KISS1R compared to control mice (Figure 2.2 A-C). Using anti-human Ki67 
antibody, human tumor cell proliferation was visualized within tumors in the lung 
sections adjacent to the H&E stained lung sections thus confirming the presence 
of human cell metastases (Figure 2.2A). Hence, our data indicates that KISS1R 





Figure 2.1. KISS1R depletion reduces MDA-MB-231 primary tumor 
formation in vivo. (A) Representative Western blots showing expression levels 
of endogenous KISS1R MDA-MB-231 in cell populations used for injections. 
Western blot analysis with goat polyclonal anti-KISS1R (N-20) antibody. 
Quantification of Western blot expression normalized to β-actin (n=4). One-way 
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns 
represent protein expression ± SEM. (B) MDA-MB-231 cells expressing KISS1R 
shRNA or scrambled control where cultured in 96 well plate and viability was 
determined by MTT assay (n=4). Columns represent absorbance measured at 
550nm subtract background reading at 700nm, ± SEM. (C) Primary tumors 
formed over 5 weeks formed within the mammary fat pad of NOD/SCID/IL2Rγ 
null mice using MDA-MB-231 breast cancer cells expressing scrambled control 
shRNA or KISS1R shRNA (106 cells/mouse; 5 mice/cell population). One-way 
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Points 




Figure 2.2. KISS1R depletion reduces lung metastatic burden. (A) At 5 
weeks post-inject, mice were sacrificed and assessed for metastatic burden in 
the lungs. Representative images of lung tissue subjected to either hematoxylin 
and eosin or Ki67 staining detected with rabbit monoclonal anti-Ki67 antibody 
followed by anti-rabbit HRP conjugate secondary antibody. Lung metastasis 
outlined with green. Scale bar, 100 μm. The extent of lung metastasis was 
determined by area of lung (B) and number of lung metastases (C) (4 
sections/mouse, 5 mice per cell population). One-way ANOVA followed by 
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent lung area and 
number of metastases ± SEM , respectively. 
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KISS1R depletion reduces breast cancer angiogenesis 
To determine the mechanism by which KISS1R depletion reduced breast 
cancer metastasis, we investigated the role of KISS1R in the promotion of 
angiogenesis. Using the primary tumor sections from the orthotopic xenograft 
experiments, we stained for blood vessel formation using CD31, a marker for 
endothelial cells (Figure 2.3A). In the primary tumors depleted of KISS1R, we 
observed a reduction in the blood vessel density in tumors depleted of KISS1R 
(Figure 2.3B). Vascular endothelial growth factor (VEGF) and transcription factor 
hypoxia-inducible factor-1(HIF-1α) are two proteins whose expression has been 
demonstrated to increase with breast cancer progression, leading to the 
promotion of angiogenesis (15, 16). Hence, we assessed whether KISS1R 
regulated the expression of VEGF and HIF-1α in MDA-MB-231 cells. We 
observed that a reduction in KISS1R expression in MDA-MB-231 cells was 
associated with a reduction in both VEGF and HIF-1α (Figure 2.4). Hence, our 
results implicate a possible mechanism by which KISS1R promotes breast 





Figure 2.3. Depletion of KISS1R reduces breast cancer angiogenesis in 
vivo. (A) Representative images of blood vessels stained with CD31 mouse in 
primary tumors subjected to hematoxylin counter stain. Mouse CD31 was 
detected with rat monoclonal anti-mouse CD31 antibody followed by anti-rat HRP 
conjugate secondary antibody. Scale bar, 100 μm. (B) Number blood vessels in 
primary tumors formed within the mammary fat pad of NOD/SCID/IL2rγ mice 
injected with MDA-MB-231 breast cancer cells expressing scrambled control 
shRNA or KISS1R shRNA (5 mice/cell population). One-way ANOVA followed by 
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent number of 




Figure 2.4. KISS1R expression regulates the pro-angiogenic factors in 
breast cancer cells. Representative Western blots showing expression levels of 
endogenous VEGF and HIF-1α in MDA-MB-231 cells depleted of KISS1R. 
Western blot analysis with a rabbit polyclonal anti-HIF-1α antibody and rabbit 
polyclonal anti-VEGF antibody (n=4). Quantification of Western blot expression 
normalized to β-Actin. One-way ANOVA followed by Dunnett’s multiple 
comparison test: *, P < 0.05. Columns represent protein expression ± SEM.  
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KISS1R depletion reduces the mesenchymal phenotype of human breast 
cancer cell lines MDA-MB-231 and Hs578T 
 To better understand the mechanism by which KISS1R signaling regulates 
metastasis, we investigated the effect of KISS1R depletion on breast cancer 
mesenchymal phenotype. Hence we depleted KISS1R in two invasive human 
adenocarcinoma breast cancer cell lines, MDA-MB-231 and Hs578T. Expression 
of two different KISS1R shRNA constructs in Hs578T cells depleted KISS1R 
expression as verified through western blot (Figure 2.5A) and did not affect cell 
viability (Figure 2.5B). Upon depletion of KISS1R we observed a reduction in 
mesenchymal morphology as characterized by a loss of long, spindle shaped 
morphology of invasive breast cancers cells (Figure 2.5C).  Furthermore, a 
reduction of KISS1R expression decreased actin stress fiber formation in breast 
cancer cells (Figure 2.6). We have previously reported that overexpression of 
KISS1R stimulates epithelial-to-mesenchymal transition in the non-malignant 
human MCF10A mammary epithelial cells and the human breast cancer SKBR3 
cells (2). Hence, we assessed whether depletion of KISS1R regulated the 
expression of mesenchymal markers smooth muscle actin, β-catenin, and 
Snail/Slug. We found that the depletion of KISS1R resulted in the loss of 
expression of these markers in MDA-MB-231 and Hs578T breast cancer cells in 
comparison to scrambled control (Figure 2.7, 2.8). Hence, our results reveal that 






Figure 2.5. Depletion of KISS1R expression reduces the mesenchymal 
phenotype of MDA-MB-231 and Hs578T breast cancer cells.  (A) 
Representative Western blots showing expression levels of endogenous KISS1R 
in Hs578T breast cancer cells expressing KISS1R shRNA or scrambled control. 
Western blot analysis with goat polyclonal anti-KISS1R (N-20) antibody. 
Quantification of Western blot expression normalized to β-actin (n=3). One-way 
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns 
represent protein expression ± SEM. (B) Hs578T cells expressing KISS1R 
shRNA or scrambled control where cultured in 96 well plate and viability was 
determined by MTT assay (n=3-4). Columns represent absorbance measured at 
550nm subtract background reading at 700nm, ± SEM. (C) Representative DIC 
images of MDA-MB-231 and Hs578T breast cancer cells expressing scrambled 





Figure 2.6. Reduction in KISS1R expression reduces stress fiber formation 
in MDA-MB-231 and Hs578T cells.  F-actin stained with phalloidin -Alexa Fluor 
555 (red) and nuclei stained using Hoechst 33258 (blue) and visualized by 
confocal microscopy. Images representative of three independent experiments. 





Figure 2.7. Decreased expression of KISS1R reduces mesenchymal 
markers in MDA-MB-231 cells.  Representative Western blots showing 
expression levels of KISS1R and mesenchymal markers β-catenin (n=4), 
Snail/Slug (n=3) and smooth muscle actin (SMA) (n=3) in MDA-MB-231 breast 
cancer cells expressing scrambled shRNA or KISS1R shRNA. Western blot 
analysis performed with mouse monoclonal anti-β-catenin, rabbit polyclonal anti-
Snail/Slug, and mouse monoclonal anti-smooth muscle actin. Quantification of 
Western blot expression normalized to β-actin. One-way ANOVA followed by 
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent protein 






Figure 2.8. Decreased expression of KISS1R reduces mesenchymal 
markers in Hs578T cells.  Representative Western blots showing expression 
levels of KISS1R and mesenchymal markers β-catenin (n=3) and Snail/Slug 
(n=3) in Hs578T breast cancer cells expressing scrambled shRNA or KISS1R 
shRNA. Western blot analysis performed with mouse monoclonal anti-β-catenin 
and rabbit polyclonal anti-Snail/Slug. Quantification of Western blot expression 
normalized to β-actin. One-way ANOVA followed by Dunnett’s multiple 




KISS1R depletion reduces breast cancer cell migration. 
The ability of cancer cells to metastasize is dependent on two important 
cellular functions, the cell’s capacity to invade or degrade the surrounding tissue 
as well as the cell’s ability to migrate through the space, away from the primary 
tumor (17-19). To assess a role of KISS1R in promoting migration, we first used 
scratch migration assays. We found that reduction of KISS1R expression 
decreased the distance migrated in comparison to cells expressing scrambled 
control (Figure 2.9). We have previously reported that kisspeptin-10 increases 
migration and invasion at maximal response observed using 100 nM 
concentration, thus all of our following experiments were conducted using 100 
nM kisspeptin-10 (2, 3, 12, 20, 21). Migration was also measured using the 
transwell chamber migration assays. MDA-MB-231 or Hs578T cells expressing 
scrambled control or KISS1R shRNA were seeded in serum-free media or serum 
free media containing 100 nM kisspeptin-10 and allowed to migrate for 20 hours. 
The depletion of KISS1R reduced basal migration as well as kisspeptin-10 
stimulated migration (Figure 2.10). Moreover, we saw no differences in cell 
proliferation suggesting that the observed differences in scratch closure and 
transwell migration assays are due to changes in cell migration and not increase 
in cellular proliferation (Figure 2.11).  Hence, these results suggest that KISS1R 





Figure 2.9. Depletion of KISS1R inhibits breast cancer scratch wound 
closure. Decreased expression of KISS1R reduces the distance closed by (A) 
MDA-MB-231 and (B) Hs578T cells in a scratch assay over an 18 hour and 15 
hour period, respectively. Two-way ANOVA followed by Bonferroni post hoc test: 
a, P < 0.05 for KISS1R shRNA construct #1 vs. scrambled control; b, P <0.05 






Figure 2.10. Depletion of KISS1R expression inhibits MDA-MB-231 and 
Hs578T cell transwell chamber migration. Depletion of KISS1R in (A) MDA-
MB-231 and (B) Hs578T cells decreases the number of cells migrated towards 
10% fetal bovine serum (FBS) under basal conditions and inhibits kisspeptin-10 
induced cell migration (n=3-6). Two-way ANOVA followed by Bonferroni post hoc 
test: a, P < 0.05 for significant difference vs. scrambled control non-stimulated; b, 
P < 0.05 for significant difference vs. scrambled control 100 nM kisspeptin-10. 





Figure 2.11. KISS1R depletion does not affect cell proliferation rate over a 
72 hour period. (A) MDA-MB-231 or (B) Hs578T cells expressing KISS1R 




Decreased KISS1R expression diminishes breast cancer cell invasion. 
Both malignant and non-malignant breast cell lines can be cultured in 
Matrigel, a reconstituted extracellular matrix that mimics the in vivo tumor micro-
environment (2-4, 7). MDA-MB-231 and Hs578T breast cancer cells cultured in 
the three-dimension (3D) Matrigel assay formed less invasive (stellate) colonies 
when depleted of KISS1R in comparison to cells expressing scrambled control 
(Figure 2.12, 2.13). Furthermore, we observed that KISS1R depletion reduced 
basal and kisspeptin-10 induced breast cancer cell invasion using transwell 
membrane invasion assays (Figure 2.14). Overall, these findings suggest that 
KISS1R signaling promotes the invasiveness of breast cancer cells and that this 




Figure 2.12. Decreased KISS1R expression inhibits MDA-MB-231 breast 
cancer cell invasion in three-dimensional Matrigel assay. MDA-MB-231 cells 
expressing KISS1R shRNA suspended in Matrigel for 5 days display reduced 
growth of invasive stellate structures relative to cells expressing scrambled 
control (n=3-5). Scale bar, 100 μm.  Two-way ANOVA followed by Bonferroni 
post hoc test: a, P < 0.05 for KISS1R shRNA construct #1 vs. scrambled control; 




Figure 2.13. Decreased KISS1R expression inhibits Hs578T breast cancer 
cell invasion in three-dimensional Matrigel assay. Hs578T cells expressing 
KISS1R shRNA suspended in Matrigel for 5 days display reduced growth of 
invasive stellate structures relative to cells expressing scrambled control (n=3). 
Scale bar, 100 μm.  Two-way ANOVA followed by Bonferroni post hoc test: a, P 
< 0.05 for KISS1R shRNA construct #1 vs. scrambled control; b, P <0.05 KISS1R 




Figure 2.14. Depletion of KISS1R expression inhibits breast cancer cell 
invasion in Matrigel transwell chamber invasion assay. Decreased KISS1R 
expression reduces (A) MDA-MB-231 and (B) Hs578T cell invasion towards 10% 
fetal bovine serum (FBS) at basal conditions and inhibits kisspeptin-10 induced 
invasion (n=3-5). Two-way ANOVA followed by Bonferroni post hoc test: a, P < 
0.05 for significant difference vs. scrambled control non-stimulated; b, P < 0.05 
for significant difference vs. scrambled control 100 nM kisspetin-10. Columns 
represent cells invaded to lower chamber ± SEM 
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KISS1R depletion decreases colony formation by breast cancer cells 
To establish a role for KISS1R in breast cancer tumorigenicity, we 
conducted the anchorage independent assays. MDA-MB-231 cells depleted of 
KISS1R or expressing the scrambled control were cultured in agar and then the 
numbers of colonies that formed were counted. Compared to the scrambled 
control, cells depleted of KISS1R showed a dramatic decrease in colony 
formation (Figure 2.15). Thus, our data suggest that KISS1R expression 
regulates the ability of metastatic breast cancer cells to grow in an anchorage-
independent environment suggesting a mechanism by which KISS1R signaling 





Figure 2.15. KISS1R depletion in MDA-MB-231 cells reduces anchorage 
independent growth. (A) MDA-MB-231 expressing scrambled control shRNA or 
KISS1R shRNA was grown in agarose for 6 weeks (n=4-5). Reduction in KISS1R 
decreased the number of colonies greater than 50 μm in diameter as compared 
to cells expressing scrambled control. One-way ANOVA followed by Dunnett’s 
multiple comparison test: *, P < 0.05. Columns represent colonies greater than 
50 μm in diameter, ± SEM. (B) Representative pictures of MDA-MB-231 cellular 
colonies at 6 weeks. Scale bar, 200 μm. 
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Kisspeptin Signaling Stimulates Invadopodia Formation 
Our data thus far indicates that KISS1R signaling plays a role in promoting 
breast cancer cell invasion. To evaluate the mechanism by which KISS1R 
promotes cell invasion, we used a gelatin degradation assay to assess the ability 
of kisspeptin-10 to stimulate invadopodia. Invadopodia formed by cells degrade 
the gelatin leaving darkened areas or “holes” in the areas depleted of gelatin (22, 
23). The ability for invadopodia to form and degrade the gelatin is dependent on 
cortactin and F-actin; these two proteins display a punctate pattern and co-
localize at points of degradation (23, 24). Hence, invadopodia formation was 
determined by measuring the number of cells forming F-actin-cortactin co-
localization punctate pattern with associated underlying gelatin degradation 
(Figure 2.16A). MDA-MB-231 or Hs578T cells were plated on gelatin for 24 hours 
and then stimulated with 100 nM kisspeptin-10 for 30 minutes. Upon kisspeptin-
10 stimulation, the number of cells with invadopodia formation increased 
significantly compared to basal levels (Figure 2.16B). Furthermore, we observed 
that pre-treatment with the KISS1R antagonist, P-234 (1 μM), inhibited 
kisspeptin-10 induced invadopodia formation (Figure 2.16B). Overall, our data 
reveals for the first time that KISS1R stimulates invadopodia formation in breast 




Figure 2.16. Activation of KISS1R promotes invadopodia formation. (A) 
Representative pictures of invadopodia formation via actin (phalloidin, red) and 
cortactin (blue) organization promoting gelatin degradation. Cortactin 
immunostaining detected using mouse monoclonal anti-cortactin antibody, 
followed by DyLight 350 secondary antibody. Images are representative of three 
independent experiments. Scale bar, 10 μm. (B) Treatment of MDA-MB-231 or 
Hs578T breast cancer cells with 100 nM kisspeptin-10 causes an increase in the 
number if cells with invadopodia formation. Pre-treatment with the KISS1R 
antagonist, P-234, inhibits kisspeptin-10 induced invadopodia formation (n=3). 
One-way ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. 
Columns represent percent of cells with invadopodia ± SEM.
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Kisspeptin stimulation increases cortactin and cofilin activity 
Invadopodia formation is dependent on the activity of two proteins, 
cortactin and cofilin (23, 25). The activities of both of these proteins are 
dependent on their phosphorylation status, where dephosphorylation can be 
associated with increased activity and maturation of invadopodia (23, 26-29). To 
evaluate if KISS1R regulates the activity of cofilin and cortactin we stimulated 
MDA-MB-231 breast cancer cells with kisspeptin-10 (100 nM) for 5 and 15 
minutes and evaluated changes in phosphorylation of either cortactin (Y421) or 
cofilin (S3). Upon stimulation of the MDA-MB-231 cells with kisspeptin-10, we 
saw a decrease in phosphorylation of both proteins, with maximal 
dephosphorylation occurring for cortactin at 5 minutes and maximal 
dephosphorylation for cofilin at 15 minutes (Figure 2.17). These results 
demonstrate that kisspeptin-10 treatment of breast cancer cells increases the 
activity of the proteins involved in invadopodia formation. Furthermore, we found 
that upon depletion of KISS1R, kisspeptin-10 mediated dephosphorylation of 
cortactin and cofilin was inhibited at both time points (Figure 2.18). Our results 
thus indicate that kisspeptin-10 signaling via KISS1R stimulates cortactin and 
cofilin activity necessary to promote invadopodia formation in breast cancer cells. 
Furthermore, we observed that KISS1R is co-localized in invadopodia with 
cortactin, IQGAP1, EGFR, and MT1-MMP, proteins essential for the formation 





Figure 2.17. KISS1R signaling promotes cortactin and cofilin activity. 
Treatment of MDA-MB-231 breast cancer cells with 100 nM kisspeptin-10 caused 
a decrease in the phosphorylation of cofilin and cortactin. Western blot analysis 
with a rabbit polyclonal anti-phospho cortactin (Y421) antibody, rabbit polyclonal 
anti-phospho cofilin (S3), mouse monoclonal anti-cortactin, and mouse 
monoclonal anti-cofilin. Phosphorylation levels are normalized to total cofilin or 
total cortactin (n=5). One-way ANOVA followed by Dunnett’s multiple comparison 





Figure 2.18. Depletion of KISS1R expression inhibits kisspeptin-10 induced 
decreases in cortactin and cofilin activity. Treatment with kisspeptin-10 100 
nM was unable to decrease cofilin and cortactin phosphorylation of MDA-MB-231 
breast cancer cells depleted of KISS1R. Phosphorylation levels are normalized to 
total cofilin or total cortactin (n=3-5). One-way ANOVA followed by Bonferroni 
post hoc test: a, P < 0.05 for significant difference vs. scrambled control 
kisspeptin-10 0 minutes; b, P < 0.05 for significant difference vs. scrambled 
control kisspeptin-10 5 minutes; c, P < 0.05 significant difference vs. scrambled 




Figure 2.19. KISS1R co-localizes with endogenous cortactin, EGFR, MT1-
MMP, and IQGAP1 in invadopodia.  Co-localization of endogenous KISS1R 
with (A) MT1-MMP and cortactin or (B) MT1-MMP and EGFR or (C) MT1-MMP 
and IQGAP1or (D) IQGAP1 and cortactin. Images are representative of three 
independent experiments. Scale bar, 10 μm. KISS1R immunofluorescence 
detected using goat polyclonal KISS1R (N-20) antibody followed by an anti-goat 
Alexa Fluor 555 (red); EGFR detected using mouse monoclonal anti-EGFR 
antibody followed by anti-mouse DyLight 350 (blue); MT1-MMP detected using 
rabbit monoclonal anti-MT1-MMP antibody followed by anti-rabbit Alexa Fluor 
488 (green); Cortactin detected using mouse monoclonal anti-cortactin antibody 
followed by anti-mouse DyLight 350 (blue);  IQGAP1 detected using either 
mouse or rabbit monoclonal anti-IQGAP1 antibody followed by anti-mouse 
DyLight 350 (blue) or anti-rabbit Alexa Fluor 488 (green).
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Kisspeptin-10 induces MT1-MMP Tyrosine Phosphorylation.  
The activation of MT1-MMP by tyrosine phosphorylation of Tyr 573 by Src 
kinase has been recognized to increase cellular migration and matrix-
degradation in 3D matrices (31, 32). Furthermore, an in vivo study using a 
subcutaneous tumor injection into the flanks of mice observed that Tyrosine 573 
mutation inhibiting tyrosine phosphorylation resulted in decreased tumor 
progression, increased tumor necrosis, and increased survival suggesting a 
direct role for MT1-MMP tyrosine phosphorylation in cancer progression (33). 
Thus, to evaluate if KISS1R signaling could activate MT1-MMP, we stimulated 
MDA-MB-231 cells with kisspeptin-10 100 nM for 5 and 15 minutes and observed 
for changes in MT1-MMP tyrosine phosphorylation. Using immunoprecipitation of 
MT1-MMP and an anti-tyrosine-phosphorylation antibody, we observed increase 
in tyrosine phosphorylation at both 5 and 15 minutes of kisspeptin-10 stimulation, 
with a significant increase at 5 minutes (Figure 2.20). Thus, this result suggests 
KISS1R stimulation may cause an increased MT1-MMP activity which is 





Figure 2.20. Kisspeptin stimulation increases MT1-MMP tyrosine 
phosphorylation. Treatment of MDA-MB-231 breast cancer cells with 100 nM 
kisspeptin-10 causes an increase in MT1-MMP tyrosine phosphorylation. 
Western blot analysis with a mouse monoclonal anti-phosphotyrosine antibody 
and rabbit monoclonal anti-MT1-MMP. Phosphorylation levels are normalized to 
total MT1-MMP (n=3). One-way ANOVA followed by Dunnett’s multiple 
comparison test: *, P<0.05. Columns represent protein phosphorylation ± SEM.
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β-arrestin2 regulates kisspeptin mediated invadopodia formation 
KISS1R promotes invasion by stimulating the secretion and activity of 
MMP-9 via a β-arrestin2 dependent mechanism (3) Likewise, β-arrestin2 has 
shown to be a direct binding partner for the invadopodia precursors cofilin, 
cortactin, and IQGAP1 (6, 34, 35). Hence, we determined whether β-arrestin2 is 
also localized to invadopodia. Indeed, we observed that β-arrestin2 is localized to 
invadopodia and co-localizes with MT1-MMP, cortactin and KISS1R suggesting a 
possible role for β-arrestin2 in regulating KISS1R mediated invadopodia 
formation (Figure 2.21). Therefore, to investigate a role of β-arrestin2 in 
invadopodia formation, we depleted β-arrestin2 in MDA-MB-231 cells as verified 
through western blot (Figure 2.22A). Using the gelatin degradation assay, we 
observed a reduction of invadopodia formation in cells depleted of β-arrestin2 
(Figure 2.22B). Furthermore, β-arrestin2 depletion inhibited the ability of 
kisspeptin-10 100 nM to increase invadopodia formation (Figure 2.22B). Finally, 
we investigated if β-arrestin2 regulated kisspeptin-10 mediated decrease in 
phosphorylation of both cortactin and cofilin. We found that upon depletion of β-
arrestin2, kisspeptin-10 mediated dephosphorylation of cortactin and cofilin was 




Figure 2.21. β-arrestin2 co-localizes with cortactin, MT1-MMP, and KISS1R 
in invadopodia.  Co-localization of endogenous β-arrestin2 with (A) MT1-MMP 
and cortactin or (B) KISS1R and MT1-MMP. Images are representative of three 
independent experiments. Scale bar, 10 μm. β-arrestin2 detected using goat 
polyclonal anti-β-arrestin2 followed by anti-goat Alexa Fluor 555 (red); MT1-MMP 
detected using rabbit monoclonal anti-MT1-MMP antibody followed by anti-rabbit 
Alexa Fluor 488 (green); cortactin detected using a mouse monoclonal anti-
cortactin antibody followed by anti-mouse DyLight 350 (blue); KISS1R 
immunofluorescence detected using goat polyclonal KISS1R (N-20) antibody 





Figure 2.22. β-arrestin2 depletion inhibits invadopodia formation. (A) 
Representative Western blots showing expression levels of β-arrestin2 in MDA-
MB-231 breast cancer cells expressing β-arrestin2 shRNA or scrambled control. 
Western blot analysis with mouse monoclonal anti-β-arrestin2 antibody. 
Quantification of Western blot expression normalized to β-actin (n=3). One-way 
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns 
represent protein expression ± SEM. (B) Depletion of β-arrestin2 decreases 
invadopodia formation at basal conditions and inhibits kisspeptin mediated 
invasion. Two-way ANOVA followed by Bonferroni post hoc test: a, P < 0.05 for 
significant difference vs. scrambled control kisspeptin-10 0 minutes; b, P < 0.05 
for significant difference vs. scrambled control kisspeptin-10 5 minutes; c, P < 
0.05 significant difference vs. scrambled control kisspeptin-10 15 minutes. 




Figure 2.23. β-arrestin2 regulates kisspeptin-10 induced cortactin and 
cofilin activity. β-arrestin2 depletion in MDA-MB-231 breast cancer cells inhibits 
kisspeptin-10 100 nM induced cofilin and cortactin dephosphorylation. 
Phosphorylation levels are normalized to total cofilin or total cortactin (n=3-5). 
Two-way ANOVA followed by Bonferroni post hoc test: a, P < 0.05 for significant 
difference vs. scrambled control kisspeptin-10 0 minutes; b, P < 0.05 for 
significant difference vs. scrambled control kisspeptin-10 5 minutes; c, P < 0.05 
significant difference vs. scrambled control kisspeptin-10 15 minutes. Columns 
represent protein phosphorylation ± SEM.  
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KISS1R signaling promotes breast cancer extravasation in vivo. 
The ability of cells to form invadopodia has been linked to the capability of 
cancer cells to intravasate and extravasate during metastasis (18, 36). 
Extravasation is the event of metastasis where cancer cells leave the blood 
vasculature and enter the surrounding tissue. The chick chorioallantoic 
membrane (CAM) assay is a well-established model to measure cell 
extravasation by cancer cells in vivo (18, 36). MDA-MB-231 cells were injected 
into the chorioallantoic membrane of 12 day old chick embryos. A significant 
increase in cell extravasation was observed with 10 nM or 100 nM kisspeptin-10 
treatments (Figure 2.24). Pre-treatment of the cells with 1 μM P-234 KISS1R 
antagonist or 1 μM AG-1478 EGFR antagonist or combination of both inhibitors 
significantly blocked extravasation (Figure 2.24). Also, KISS1R depletion 
significantly reduced MDA-MB-231 cell extravasation in comparison scrambled 
controls treated with vehicle or kisspeptin-10 10 nM (Figure 2.29). Overall, these 
results suggest that activation of KISS1R stimulates breast cancer cell 




Figure 2.24. KISS1R antagonism attenuates MDA-MB-231 breast cancer cell 
extravasation in the chick chorioallantoic membrane (CAM) assay. 
Kisspeptin-10 (10 nM) significantly increased the number of MDA-MB-231 cells 
extravasating compared to vehicle control (n=14-18). Pre-treatment of cells with 
KISS1R antagonist P-234, and/or EGFR antagonist AG 1478 significantly 
reduced the percentage of cells extravasated compared to vehicle control or 10 
nM kisspeptin-10 treatment (n=3-6). One-way ANOVA followed by Bonferroni 
post hoc test: a, P<0.05 compared to vehicle treated scrambled control; b, 
P<0.05 compared to 10 nM kisspetin-10 treated scrambled control.  Columns 





Figure 2.25. Depletion of KISS1R decreases breast cancer cell 
extravasation. Decreased KISS1R expression in MDA-MB-231 cells inhibits cell 
extravasation compared to scrambled control vehicle or 10 nM kisspeptin-10 
treatments (control groups: n=14-18; KISS1R shRNA groups: n=5-6). Two-way 
ANOVA followed by Bonferroni post hoc test: a, P<0.05 compared to vehicle 
treated scrambled control; b, P<0.05 compared to 10 nM kisspeptin-10 treated 
scrambled control.  Columns represent % cell extravasation ± SEM.  
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β-arrestin2 regulates KISS1R induced extravasation of breast cancer cells. 
Thus far our data supports the premise that β-arrestin2 regulates 
kisspeptin-10 induced invadopodia formation. Hence, we sought to investigate 
whether KISS1R stimulates breast cancer extravasation via β-arrestin2. MDA-
MB-231 cells depleted of β-arrestin2 were used in the CAM assay. Depletion of 
β-arrestin2 decreased basal and kisspeptin-10 induced extravasation as 
compared to scrambled controls (Figure 2.26). These results demonstrate that β-





Figure 2.26. β-arrestin depletion attenuates breast cancer cell 
extravasation. Depletion of β-arrestin2 in MDA-MB-231 cells significantly 
reduced percent cell extravasation in comparison scrambled control vehicle and 
10 nM kisspeptin-10 treatments (control groups: n=14-18, β-arrestin shRNA 
groups: n=5-6). Two-way ANOVA followed by Bonferroni post hoc test: a, P<0.05 
compared to vehicle treated scrambled control; b, P<0.05 compared to 10nM 





1. L. Hughes, C. Malone, S. Chumsri, A.M. Burger, and S. McDonnell. 
Characterisation of breast cancer cell lines and establishment of a novel 
isogenic subclone to study migration, invasion and tumourigenicity. 
Clinical & experimental metastasis. 25:549-557 (2008). 
2. D. Cvetkovic, M. Dragan, S.J. Leith, Z.M. Mir, H.S. Leong, M. Pampillo, 
A.V. Babwah, and M. Bhattacharya. KISS1R Induces Invasiveness of 
Estrogen Receptor-Negative Human Mammary Epithelial and Breast 
Cancer Cells. Endocrinology(2013). 
3. M. Zajac, J. Law, D.D. Cvetkovic, M. Pampillo, L. McColl, C. Pape, G.M. 
Di Guglielmo, L.M. Postovit, A.V. Babwah, and M. Bhattacharya. GPR54 
(KISS1R) transactivates EGFR to promote breast cancer cell 
invasiveness. PloS one. 6:e21599 (2011). 
4. T.T. Li, M. Alemayehu, A.I. Aziziyeh, C. Pape, M. Pampillo, L.M. Postovit, 
G.B. Mills, A.V. Babwah, and M. Bhattacharya. Beta-arrestin/Ral signaling 
regulates lysophosphatidic acid-mediated migration and invasion of 
human breast tumor cells. Molecular cancer research : MCR. 7:1064-1077 
(2009). 
5. A.K. Croker, D. Goodale, J. Chu, C. Postenka, B.D. Hedley, D.A. Hess, 
and A.L. Allan. High aldehyde dehydrogenase and expression of cancer 
stem cell markers selects for breast cancer cells with enhanced malignant 
and metastatic ability. Journal of cellular and molecular medicine. 
13:2236-2252 (2009). 
6. M. Alemayehu, M. Dragan, C. Pape, I. Siddiqui, D.B. Sacks, G.M. Di 
Guglielmo, A.V. Babwah, and M. Bhattacharya. beta-Arrestin2 regulates 
lysophosphatidic acid-induced human breast tumor cell migration and 
invasion via Rap1 and IQGAP1. PloS one. 8:e56174 (2013). 
7. G.Y. Lee, P.A. Kenny, E.H. Lee, and M.J. Bissell. Three-dimensional 
culture models of normal and malignant breast epithelial cells. Nature 
methods. 4:359-365 (2007). 
8. A.L. Allan, R. George, S.A. Vantyghem, M.W. Lee, N.C. Hodgson, C.J. 
Engel, R.L. Holliday, D.P. Girvan, L.A. Scott, C.O. Postenka, W. Al-Katib, 
L.W. Stitt, T. Uede, A.F. Chambers, and A.B. Tuck. Role of the integrin-
binding protein osteopontin in lymphatic metastasis of breast cancer. The 
American journal of pathology. 169:233-246 (2006). 
9. E. Arpaia, H. Blaser, M. Quintela-Fandino, G. Duncan, H.S. Leong, A. 
Ablack, S.C. Nambiar, E.F. Lind, J. Silvester, C.K. Fleming, A. Rufini, 
M.W. Tusche, A. Brustle, P.S. Ohashi, J.D. Lewis, and T.W. Mak. The 
interaction between caveolin-1 and Rho-GTPases promotes metastasis by 
controlling the expression of alpha5-integrin and the activation of Src, Ras 
and Erk. Oncogene. 31:884-896 (2012). 
10. H.S. Leong, N.F. Steinmetz, A. Ablack, G. Destito, A. Zijlstra, H. 
Stuhlmann, M. Manchester, and J.D. Lewis. Intravital imaging of 
embryonic and tumor neovasculature using viral nanoparticles. Nat 
Protoc. 5:1406-1417 (2010). 
93 
 
11. V.F. Maksimov, I.M. Korostyshevskaya, and S.A. Kurganov. Functional 
morphology of chorioallantoic vascular network in chicken. B Exp Biol 
Med+. 142:367-371 (2006). 
12. M. Pampillo, N. Camuso, J.E. Taylor, J.M. Szereszewski, M.R. Ahow, M. 
Zajac, R.P. Millar, M. Bhattacharya, and A.V. Babwah. Regulation of 
GPR54 signaling by GRK2 and {beta}-arrestin. Molecular endocrinology. 
23:2060-2074 (2009). 
13. D.F. Quail, G. Zhang, L.A. Walsh, G.M. Siegers, D.Z. Dieters-Castator, 
S.D. Findlay, H. Broughton, D.M. Putman, D.A. Hess, and L.M. Postovit. 
Embryonic morphogen nodal promotes breast cancer growth and 
progression. PloS one. 7:e48237 (2012). 
14. S. Valastyanand R.A. Weinberg. Tumor metastasis: molecular insights 
and evolving paradigms. Cell. 147:275-292 (2011). 
15. B.P. Schneiderand K.D. Miller. Angiogenesis of breast cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical 
Oncology. 23:1782-1790 (2005). 
16. R. Bos, H. Zhong, C.F. Hanrahan, E.C. Mommers, G.L. Semenza, H.M. 
Pinedo, M.D. Abeloff, J.W. Simons, P.J. van Diest, and E. van der Wall. 
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. 
Journal of the National Cancer Institute. 93:309-314 (2001). 
17. M. Sidani, D. Wessels, G. Mouneimne, M. Ghosh, S. Goswami, C. 
Sarmiento, W. Wang, S. Kuhl, M. El-Sibai, J.M. Backer, R. Eddy, D. Soll, 
and J. Condeelis. Cofilin determines the migration behavior and turning 
frequency of metastatic cancer cells. The Journal of cell biology. 179:777-
791 (2007). 
18. B. Gligorijevic, J. Wyckoff, H. Yamaguchi, Y.R. Wang, E.T. Roussos, and 
J. Condeelis. N-WASP-mediated invadopodium formation is involved in 
intravasation and lung metastasis of mammary tumors. Journal of cell 
science. 125:724-734 (2012). 
19. P. Mukhopadhyay, I. Lakshmanan, M.P. Ponnusamy, S. Chakraborty, M. 
Jain, P. Pai, L.M. Smith, S.M. Lele, and S.K. Batra. MUC4 Overexpression 
Augments Cell Migration and Metastasis through EGFR Family Proteins in 
Triple Negative Breast Cancer Cells. PloS one. 8:(2013). 
20. J.M. Navenot, Z. Wang, M. Chopin, N. Fujii, and S.C. Peiper. Kisspeptin-
10-induced signaling of GPR54 negatively regulates chemotactic 
responses mediated by CXCR4: a potential mechanism for the metastasis 
suppressor activity of kisspeptins. Cancer research. 65:10450-10456 
(2005). 
21. A.K. Roseweir, A.S. Kauffman, J.T. Smith, K.A. Guerriero, K. Morgan, J. 
Pielecka-Fortuna, R. Pineda, M.L. Gottsch, M. Tena-Sempere, S.M. 
Moenter, E. Terasawa, I.J. Clarke, R.A. Steiner, and R.P. Millar. Discovery 
of potent kisspeptin antagonists delineate physiological mechanisms of 
gonadotropin regulation. The Journal of neuroscience : the official journal 
of the Society for Neuroscience. 29:3920-3929 (2009). 
22. V.V. Artym, Y. Zhang, F. Seillier-Moiseiwitsch, K.M. Yamada, and S.C. 
Mueller. Dynamic interactions of cortactin and membrane type 1 matrix 
94 
 
metalloproteinase at invadopodia: defining the stages of invadopodia 
formation and function. Cancer research. 66:3034-3043 (2006). 
23. M. Oser, H. Yamaguchi, C.C. Mader, J.J. Bravo-Cordero, M. Arias, X. 
Chen, V. Desmarais, J. van Rheenen, A.J. Koleske, and J. Condeelis. 
Cortactin regulates cofilin and N-WASp activities to control the stages of 
invadopodium assembly and maturation. The Journal of cell biology. 
186:571-587 (2009). 
24. C.V. Rajadurai, S. Havrylov, K. Zaoui, R. Vaillancourt, M. Stuible, M. 
Naujokas, D. Zuo, M.L. Tremblay, and M. Park. Met receptor tyrosine 
kinase signals through a cortactin-Gab1 scaffold complex, to mediate 
invadopodia. Journal of cell science. 125:2940-2953 (2012). 
25. J.J. Bravo-Cordero, M. Oser, X. Chen, R. Eddy, L. Hodgson, and J. 
Condeelis. A novel spatiotemporal RhoC activation pathway locally 
regulates cofilin activity at invadopodia. Current biology : CB. 21:635-644 
(2011). 
26. E. Meiler, E. Nieto-Pelegrin, and N. Martinez-Quiles. Cortactin tyrosine 
phosphorylation promotes its deacetylation and inhibits cell spreading. 
PloS one. 7:e33662 (2012). 
27. N. Martinez-Quiles, H.Y. Ho, M.W. Kirschner, N. Ramesh, and R.S. Geha. 
Erk/Src phosphorylation of cortactin acts as a switch on-switch off 
mechanism that controls its ability to activate N-WASP. Molecular and 
cellular biology. 24:5269-5280 (2004). 
28. X. Song, X. Chen, H. Yamaguchi, G. Mouneimne, J.S. Condeelis, and R.J. 
Eddy. Initiation of cofilin activity in response to EGF is uncoupled from 
cofilin phosphorylation and dephosphorylation in carcinoma cells. Journal 
of cell science. 119:2871-2881 (2006). 
29. M. Oserand J. Condeelis. The cofilin activity cycle in lamellipodia and 
invadopodia. Journal of cellular biochemistry. 108:1252-1262 (2009). 
30. F. Sabeh, I. Ota, K. Holmbeck, H. Birkedal-Hansen, P. Soloway, M. 
Balbin, C. Lopez-Otin, S. Shapiro, M. Inada, S. Krane, E. Allen, D. Chung, 
and S.J. Weiss. Tumor cell traffic through the extracellular matrix is 
controlled by the membrane-anchored collagenase MT1-MMP. The 
Journal of cell biology. 167:769-781 (2004). 
31. C. Nyalendo, E. Beaulieu, H. Sartelet, M. Michaud, N. Fontaine, D. 
Gingras, and R. Beliveau. Impaired tyrosine phosphorylation of membrane 
type 1-matrix metalloproteinase reduces tumor cell proliferation in three-
dimensional matrices and abrogates tumor growth in mice. 
Carcinogenesis. 29:1655-1664 (2008). 
32. C. Nyalendo, M. Michaud, E. Beaulieu, C. Roghi, G. Murphy, D. Gingras, 
and R. Beliveau. Src-dependent phosphorylation of membrane type I 
matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial 
and tumor cell migration. The Journal of biological chemistry. 282:15690-
15699 (2007). 
33. C. Nyalendo, H. Sartelet, D. Gingras, and R. Beliveau. Inhibition of 
membrane-type 1 matrix metalloproteinase tyrosine phosphorylation 
95 
 
blocks tumor progression in mice. Anticancer research. 30:1887-1895 
(2010). 
34. C.G. Pontrello, M.Y. Sun, A. Lin, T.A. Fiacco, K.A. DeFea, and I.M. Ethell. 
Cofilin under control of beta-arrestin-2 in NMDA-dependent dendritic spine 
plasticity, long-term depression (LTD), and learning. Proceedings of the 
National Academy of Sciences of the United States of America. 109:E442-
451 (2012). 
35. K. Xiao, D.B. McClatchy, A.K. Shukla, Y. Zhao, M. Chen, S.K. Shenoy, 
J.R. Yates, 3rd, and R.J. Lefkowitz. Functional specialization of beta-
arrestin interactions revealed by proteomic analysis. Proceedings of the 
National Academy of Sciences of the United States of America. 
104:12011-12016 (2007). 
36. M. Kotani, M. Detheux, A. Vandenbogaerde, D. Communi, J.M. 
Vanderwinden, E. Le Poul, S. Brezillon, R. Tyldesley, N. Suarez-Huerta, 
F. Vandeput, C. Blanpain, S.N. Schiffmann, G. Vassart, and M. 
Parmentier. The metastasis suppressor gene KiSS-1 encodes kisspeptins, 
the natural ligands of the orphan G protein-coupled receptor GPR54. The 





Chapter 3 - Discussion and Conclusions
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3.1 Summary of Novel Findings and Conclusions 
Objective #1: To investigate if KISS1R depletion inhibits human breast cancer 
metastasis using an orthotopic xenograft mouse model. 
Orthotopic xenograft tumors established with MDA-MB-231 human breast 
cancer cells depleted of KISS1R in NOD/SCID/IL2Rγ null mice resulted in 
decreased size and number of lung metastases. Hence, our results indicate that 
KISS1R signaling promotes human breast cancer metastasis in vivo. 
Objective #2: To determine the underlying mechanisms of KISS1R signaling in 
breast cancer metastasis and invadopodia formation. 
Depletion of KISS1R expression resulted in decreased orthotopic tumor 
blood vessel density and decreased expression of breast cancer cell pro-
angiogenic factors. Furthermore, KISS1R depletion resulted in a reduction in 
breast cancer cell mesenchymal phenotype and decreased breast cancer cell 
migration and invasion, two important cellular characteristics involved in cancer 
metastasis. Additionally, we found that KISS1R signals via β-arrestin2 to regulate 
invadopodia formation and extravasation. Thus, our results reveal a mechanism 
by which KISS1R signaling promotes breast cancer metastases by means of 





3.2 Contributions of Research to Current State of Knowledge 
The importance of GPCR signaling in physiological and pathological 
events is well established (1, 2). GPCR signaling involves a complex cascade of 
G protein dependent and G protein-independent signaling pathways. The 
transactivation of EGFR by GPCRs has been demonstrated in breast, lung, 
ovarian, colon and prostate cancers (3). Similarly, EGFR overexpression in 
several cancers leads to increased cell survival, proliferation, and invasion (4, 5). 
Tyrosine kinase inhibitors targeting EGFR activity have been developed. 
However, clinical results show EGFR inhibition has limited anti-metastatic affects 
due to the acquisition of drug resistance (6). Studies from our laboratory have 
revealed that KISS1R transactivates EGFR, through a β-arrestin2 and IQGAP1 
mechanism, leading to breast cancer cell invasion (7, 8). Thus, targeting both 
KISS1R and EGFR together may provide an effective therapeutic strategy in the 
prevention of breast cancer progression and metastasis. Likewise in triple-
negative breast cancer, an effective therapeutic target remains elusive resulting 
in poor patient survival (9, 10). The identification of KISS1R as novel therapeutic 
target may provide a solution for those suffering from triple-negative cancer. 
Role of KISS1R Signaling in Breast Tumor Formation and Metastasis  
In agreement with our findings, Cho and colleagues (2011) showed that 
the loss of KISS1R in heterozygotic PyMT-KISS1R+/− mice resulted in attenuated 
breast tumor initiation, growth, latency, multiplicity and lung metastasis as 
compared to the homozygotic PyMT-KISS1R+/+ mice (11). This study used a 
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MMTV-PyMT virus mediated initiation of breast cancer in mice mammary cells. 
Hence, whether KISS1R signaling in human breast cancer promotes metastasis 
remains unknown. For our study, we used a pre-clinical orthotopic xenograft 
mouse model to determine the role of KISS1R signaling in human breast cancer 
metastasis. The orthotopic xenograft mouse model has been shown to accurately 
recapitulate breast cancer gene expression profiles as seen in patient primary 
breast tumors providing an accurate model to assess the role of KISS1R in 
human breast cancer metastasis (12). Thus, our results support and augment the 
findings from the Cho et al. (2011) study by demonstrating for the first time that 
depletion in KISS1R expression in the human breast cancer cells decreases the 
number and area of lung metastases in vivo.  
In our orthotopic xenograft mouse model we observed that KISS1R 
depletion significantly reduced primary tumor volume, thus possibly contributing 
to the amount of lung metastases observed. The capacity of tumors to stimulate 
angiogenesis has been shown to control tumor growth and volume (13). We saw 
that KISS1R depletion decreased blood vessel formation in the primary tumors 
established in vivo. Furthermore, depletion of KISS1R expression in MDA-MB-
231 cells decreased the pro-angiogenic factors VEGF and HIF-1α. Cho et al. 
(2011) also reported that mouse breast cancer cells with reduction in KISS1R 
expression correlated with significant reduction in VEGF mRNA expression (11).  
A second possible mechanism by which the in vivo tumor volumes differed is 
through KISS1R regulation of cancer cellular proliferation. Cho et al. (2011) 
demonstrated that breast cancer cells cultured from KISS1R heterozygotic 
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PyMT-KISS1R+/− mice had a significant reduction in cellular proliferation 
compared to cancer cells cultured from KISS1R homozygotic PyMT-KISS1R+/+ 
mice (11). Our study did not find a difference in cell proliferation in breast cancer 
cells depleted of KISS1R over a relatively short 72 hour period. However, using 
an anchorage-independent growth assay, we observed for the first time that 
depletion of KISS1R expression reduced colony formation over a 6 week period. 
The anchorage-independent growth assay is a well-established model to 
measure cell proliferation independent of external signals and cell anchorage, 
trademarks of malignant transformation (14). Therefore, the xenograft primary 
tumors depleted of KISS1R expression may have had reduced tumor volume due 
to reduced cell proliferation. Thus, a mechanism by which KISS1R may reduce 
breast cancer metastasis is by limiting primary tumor growth through 
angiogenesis and cell proliferation, thereby reducing the number of cancer cells 
available to metastasize.  
KISS1R Signaling in Breast Cancer Invasion and Migration 
For our study, we used two human breast cancer cell lines, MDA-MB-231 
and Hs578T. These cell lines endogenously express KISS1R and EGFR, and 
kisspeptin-10 stimulation of these cells promotes migration and invasion (7, 8, 
15, 16). Our study extended these findings by demonstrating that depletion of 
KISS1R expression reduces breast cancer cells capacity to form stress fiber 
formation. Similarly, our findings showed that KISS1R depletion reduces cellular 
migration as assessed through scratch and transwell migration assays 
supporting a role for KISS1R signaling in breast cancer cell migration. However, 
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kisspeptin-10 treatment was only able to significantly increase migration as 
assessed in the transwell chamber migration assay but not the scratch assay, 
possibly due to the scratch assay’s lack of a chemical gradient as established in 
the transwell chamber assay (Supplementary Figure 1)(17).  
The ability of cancer cells to acquire a migratory phenotype is thought to 
occur through EMT. Previous findings in our lab have demonstrated that 
exogenous expression of KISS1R in MCF10A breast epithelial cells or SKBR3 
breast cancer cells initiated an EMT process, leading to increased expression of 
mesenchymal markers Snail/Slug, N-cadherin, and vimentin (7). In this study, we 
observed that depletion of KISS1R in MDA-MB-231 and Hs578T cells decreased 
expression of mesenchymal markers Snail/Slug, β-catenin, and smooth muscle 
actin. Lastly, our findings supported a role for KISS1R in breast cancer invasion 
by demonstrating that depletion of KISS1R expression resulted in decreased 
invasion of MDA-MB-231 and Hs578T cells in the transwell Matrigel invasion and 
the 3D-Matrigel invasion assays. High expression of mesenchymal markers in 
cancer cells, leading to cell invasion and migration, has been linked to increased 
cancer progression and metastasis (18). Our results support a role for KISS1R 
signaling in the promotion EMT, migration and invasion of breast cancer cells, 
thus conceivably contributing to the amount of lung metastases we observed in 





KISS1R Signaling in Invadopodia Formation 
Over the last decade, significant progress has been made in 
understanding the role of invadopodia in cell invasion and its contribution to 
cancer metastasis. First implicated in focal invasion of cells, invadopodia have 
been demonstrated to play a significant role in many metastatic events as 
revealed through in vivo studies. Invadopodia formation has been directly shown 
to be involved in cancer cell invasion into the basement membrane surrounding 
primary tumors as well as playing a direct role in cancer cell intravasation and 
extravasation (19, 20). Thus, understanding how invadopodia formation occurs 
and which proteins control invadopodia establishment and invasion is essential 
for understanding the events that regulate cancer metastasis. Previous studies 
have revealed that two proteins, cortactin and cofilin, are major invadopodia 
precursors that control invadopodia formation and maturity. Upon stimulation of 
growth factors, such as lysophosphatidic acid (LPA) or EGF, a cascade of 
signaling leads to increased activity of cofilin and cortactin through 
dephosphorylation of Serine 3 and Tyrosine 421, respectively (21-23). Growth 
factor stimulation has been shown to influence the phosphorylation status of 
cofilin and cortactin as quick as 30 seconds to as long as a hour, with peak times 
within the 3-15 minute range (20, 24, 25). Therefore, for our study we stimulated 
MDA-MB-231 cells with kisspeptin-10 for 5 and 15 minutes and observed for 
subsequent changes in phosphorylation of cortactin and cofilin. Upon kisspeptin-
10 stimulation we saw a peak dephosphorylation of cofilin at 15 minutes and 
cortactin at 5 minutes after stimulation. However, to directly determine if 
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kisspeptin signaling is involved in invadopodia formation, we used gelatin 
degradation assays, the gold standard assay, to quantify invadopodia formation 
in numerous cells (19, 20, 24, 26-28). Changes to invadopodia formation due to 
growth factor stimulation has been demonstrated to take 15 minutes to 3 hours, 
depending largely on cell type (29, 30). Upon stimulation with kisspeptin-10 we 
observed peak invadopodia formation at 30 minutes, thus all subsequent 
experiments were performed with 30 minute kisspeptin-10 stimulation 
(Supplementary Figure 2). Overall, these results suggest that kisspeptin/KISS1R 
signaling can promote the formation of invadopodia in human breast cancer cells. 
Invadopodia maturation occurs through several stages of protein 
localization and activity (31). Changes in cortactin and cofilin activity only account 
for the initial stage of invadopodia formation and protrusion. At maturation, MT1-
MMP co-localizes at the invadopodia tip and mediates ECM remodeling (31, 32). 
Phosphorylation of MT1-MMP at tyrosine 573 regulates protein activity leading to 
matrix-degradation resulting in cell invasion and tumor progression (33-35). We 
observed that stimulation with kisspeptin-10 increased tyrosine phosphorylation 
of MT1-MMP. In combination with our findings that kisspeptin increases 
invadopodia formation and gelatin degradation, the ability of kisspeptin to 
increase MT1-MMP tyrosine phosphorylation supports the previous studies 
implicating MT1-MMP tyrosine phosphorylation increases MT1-MMP invasive 
activity (33-35). However, due to the use of a non-specific tyrosine antibody, it is 
unknown if the change in tyrosine phosphorylation is that of tyrosine 573 or 
another tyrosine residue specific to KISS1R signaling. We have previously 
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demonstrated that KISS1R transactivates EGFR leading to invasion through 
increased MMP-9 activity (8). MT1-MMP degradation of ECM occurs through 
MT1-MMP mediated activation of related MMPs including MMP-9 (36). Hence, 
kisspeptin-10 mediated increase in MT1-MMP supports the previous findings that 
kisspeptin signaling leads to increase MMP-9 activity (8). Furthermore, we 
observed that KISS1R co-localizes with EGFR and MT1-MMP in invadopodia. 
Our laboratory has previously shown that KISS1R transactivates EGFR to 
mediate breast cancer cell invasion and EGFR has been demonstrated to play 
an important role in invadopodia invasion (8, 24). Thus, these results support a 
possible role for KISS1R in the formation and function of invadopodia. 
The scaffolding protein IQGAP1 is considered an oncogene and has been 
shown to promote breast cancer cell tumorigenesis (37, 38). A previous study 
investigating MT1-MMP delivery in invadopodia determined that the scaffolding 
protein IQGAP1 regulates exocyst complex and MT1-MMP delivery to the 
invadopodia tip (39). Our study supported this finding, by observing that IQGAP1 
co-localized with MT1-MMP and cortactin in invadopodia. Our laboratory has 
previously shown that IQGAP1 co-localizes with KISS1R at the leading edge of 
migrating breast cancer cells (7). Furthermore, KISS1R transactivates EGFR in 
an IQGAP1 dependent manner (7). In this study, we observed that KISS1R co-
localizes with IQGAP1 and MT1-MMP in invadopodia. Hence, KISS1R may 
regulate invadopodia invasion through regulation of IQGAP1 mediated MT1-
MMP delivery as well as regulating MT1-MMP phosphorylation. Overall, our 
results suggest that KISS1R signaling regulates the initial stages of invadopodia 
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formation through the regulation of cofilin and cortactin activity, as well as 
invadopodia maturation through regulation of MT1-MMP activity and delivery. 
Due to the evidence for invadopodia in the promotion of metastasis, the ability of 
KISS1R to promote invadopodia provides an additional mechanism by which 
KISS1R expression may influence breast cancer metastasis as seen in vivo (40, 
41). 
KISS1R Signals via β-arrestin2 in Invadopodia formation and Extravasation 
The scaffolding protein β-arrestin2 is a critical regulator of breast cancer 
cell migration and invasion (8, 42, 43). We have previously found β-arrestin2 
regulates EGFR transactivation by regulating secretion and activity of MMP-9 (7, 
8). Global proteomic analysis has demonstrated that β-arrestins interact directly 
with the invadopodia precursors, cofilin and cortactin (44). Additionally in MDA-
MB-468 breast cancer cells, cofilin activity has shown to be regulated by β-
arrestin downstream of protease-activated receptor-2 (45). However, whether β-
arrestins play a role in invadopodia formation and activity is unknown. We 
observed that depletion of β-arrestin2 decreased basal levels of invadopodia 
formation in MDA-MB-231 breast cancer cells thus supporting a role for β-
arrestin2 in invadopodia formation. Due to the ability of β-arrestin2 to bind both 
cortactin and cofilin and evidence that β-arrestin2 regulates KISS1R signaling, 
we investigated if β-arrestin2 regulated kisspeptin-10 mediated cofilin and 
cortactin dephosphorylation (44-46). Upon depletion of β-arrestin2, kisspeptin-10 
was unable to decrease both cofilin and cortactin phosphorylation. Likewise, we 
observed co-localization of β-arrestin2 with MT1-MMP and cortactin during 
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invadopodia formation. Thus, for the first time, our results suggest a role for β-
arrestin2 in kisspeptin-10 mediated invadopodia formation and invasion.  
Conclusive evidence has demonstrated that invadopodia are necessary 
for cancer intravasation and extravasation, and metastasis in vivo (40, 41). The 
chick embryonic chorioallantoic membrane (CAM) is a suitable model for 
observing cancer cell extravasation as the CAM microvasculature exhibit a 
continuous endothelial layer with an underlying basement membrane (47-49). 
Using appropriate visualization equipment, this assay enables the observation of 
cancers cells within blood capillaries, cells undergoing extravasation through the 
endothelial layer, and cancer cells within stroma (47). Previous findings in our 
laboratory have demonstrated that exogenous expression of KISS1R in SKBR3 
breast cancer cells alone could significantly increase cell extravasation over 
basal levels as observed using the CAM assay (7). Furthermore, treatment of 
SKBR3 cells expressing exogenous KISS1R with kisspeptin-10 greatly increased 
SKBR3 extravasation which in turn could be inhibited using the KISS1R 
antagonist, P-234 (7). Our findings in this study support these previous results 
whereas kisspeptin-10 treatment of MDA-MB-231 cells increased extravasation 
in the CAM assay, which was in turn inhibited with P-234. Additionally, we found 
that the EGFR antagonist, AG1478, was able to inhibit basal and kisspeptin-10 
mediated extravasation of MDA-MB-231 cells, thus supporting a role for both 
EGFR and KISS1R in breast cancer cell extravasation. Moreover, we found 
MDA-MB-231 cells depleted of KISS1R expression had reduced extravasation 
compared to basal levels and inhibited kisspeptin-10 mediated extravasation. 
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Finally, we observed that β-arrestin2 depletion significantly reduced breast 
cancer cell extravasation below basal levels and inhibited kisspeptin-10 
stimulated extravasation increase. These results demonstrate that KISS1R 
signaling contributes to breast cancer cell extravasation through a β-arrestin2 
dependent mechanism. Thus, in combination with our findings that KISS1R 
signaling plays a role in invadopodia formation and activity, it is possible that 
cancer cells with decreased KISS1R or β-arrestin2 expression are unable to form 
invadopodia which in turn inhibits extravasation and metastasis.  
3.3 Future Directions 
Our research has revealed a possible mechanism by which KISS1R 
signaling via β-arrestin2 promotes invadopodia formation (Figure 3.1). However, 
further research must be performed to fully understand kisspeptin-10 mediated 
effects of invadopodia precursor activity and localization. Previous studies, have 
reported conflicting roles for the phosphorylation status of cortactin and 
subsequent invadopodia activity. Several studies have reported that increase in 
Src mediated cortactin phosphorylation at residue Y421 is required for 
invadopodia activity (24, 25, 27). We observed that kisspeptin-10 stimulation 
caused a decrease in cortactin Y421 phosphorylation leading to increased 
invadopodia formation. These findings suggest that decreased cortactin 
phosphorylation is associated with increased cortactin activity which has also 
been reported by two previous studies, Martinez-Quiles et al. (2004) and Meiler 
et al. (2012) (21, 22). Martinez-Quiles et al. (2004) demonstrated that 
extracellular-regulated kinase (ERK) induces cortactin serine/threonine 
108 
 
phosphorylation necessary for cortactin N-WASP binding and ensuing actin 
polymerization. Consequently, Src phosphorylation of cortactin residue Y421 
inhibited the ability of cortactin to bind to N-WASP and promote actin 
polymerization (21).  
It has been established that KISS1R signaling leads to β-arrestin2 
dependent activation of ERK1/2 (15, 50). Our laboratory has previously 
demonstrated that kisspeptin-10 stimulation causes transactivation of EGFR, a 
well-known ERK activator (8, 51). Additionally, EGFR has been reported to bind 
to and increase activity of protein tyrosine phosphatase 1B (PTP1B), the 
phosphatase that causes dephosphorylation of cortactin Y421 (52, 53). 
Therefore, it is possible that kisspeptin-10 stimulation may lead to ERK activity 
though β-arrestin2 or EGFR transactivation, leading to subsequent cortactin 
mediated invadopodia formation. Hence, further research must be performed to 
evaluate such a mechanism, specifically whether kisspeptin-10 signaling leads to 





Figure 3.1 Proposed mechanism of KISS1R mediated invadopodia 
formation.  This study (green lines) revealed that kisspeptin-10 stimulation of 
KISS1R increases cortactin and cofilin activity via β-arrestin2. Previous work in 
the Bhattacharya laboratory (red lines) has demonstrated that KISS1R 
transactivates EGFR via a β-arrestin2 dependent mechanism. Consequently, 
kisspeptin-10 signaling may lead to ERK and PTP1B activity, subsequent 




Our results demonstrate for the first time that KISS1R signaling regulates 
human breast cancer metastasis. In vitro and in vivo experimentation has 
demonstrated that KISS1R expression plays a role in events that both regulate 
breast primary tumor development, such as angiogenesis, as well as events that 
that dictate metastasis, such as invadopodia formation and extravasation. 
Identifying KISS1R as a regulator of these events poses an intriguing therapeutic 
possibility; developing a therapeutic to inhibit KISS1R signaling or expression 
could both decrease breast primary tumor progression as well as inhibit breast 
cancer metastasis. Thus, this study has identified KISS1R as a novel therapeutic 
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Supplementary Figure 1. Kisspeptin-10 stimulation did not affect scratch 
wound closure. Treatment with kisspeptin-10 100 nM did not significantly 
increase migration of MDA-MB-231 breast cancer cells as assessed using the 
scratch assay (n=4). 
 
Supplementary Figure 2. Kisspeptin-10 stimulation causes peak 
invadopodia formation at 30 minutes. MDA-MB-231 breast cancer cells 
treated with kisspeptin-10 100 nM caused increased invadopodia formation at 30 
and 60 minutes (n=3-6). One-way ANOVA followed by Dunnett’s multiple 
comparison test: *, P < 0.05. Columns represent percent of cells with 
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